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ABSTRACT 
This PhD project focuses on the identification, isolation and characterization of new biocatalysts able 
to generate biologically active molecules with significant enantioselectivity. Through screening, we 
identified marine strains, from MaCuMBA (Marine Culturable Microorganism for Biotechnological 
Applications) and BIODEEP (Biotechnologies from the deep) European project collections, which 
show a marked enantioselectivity on intermediates of molecules of biological interest. 
Biotransformation substrate range included pramipexole, as main target, but it also embraces other 
common building blocks for synthetic industrial preparation. 
The stereoselective reduction of structurally different ketones using halotolerant marine yeasts 
(Meyerozyma guilliermondii and Rhodotorula mucilaginosa) was studied using cells grown and bio-
converted in seawater. The preparation of valuable chemicals through water-saving (bio)processes 
based on the direct exploitation of seawater is a significant step towards sustainable biocatalysis. By 
choosing a suitable strain, high yields and stereoselectivity could be achieved in most cases. Notably, 
high chemoselectivity and enantioselectivity were observed using R. mucilaginosa in the reduction 
of aromatic β-ketonitriles, which allowed the recovery of the optically pure corresponding alcohols; 
notably, reduction with whole cells of yeasts generally gives a mixture of undesired products, as 
observed with M. guilliermondii. 
 
Keto-reduction potential of thirty-three marine bacterium species was checked and afterwards the 
possibility to convert this substrate directly into the optically pure amine was investigated: marine 
bacteria were screened to identify transaminase activity. Based on the previous results in terms of 
halotolerance and transaminase activity, the marine bacterium strain Virgibacillus pantothenticus 
21D was selected for the genome sequencing in order to clone and express an ω-transaminase enzyme. 
 
A recombinant non-marine ketoreductase from Pichia glucozyma (KRED1-Pglu) was used for the 
enantioselective reduction of various cyclic ketones including pramipexole ketone intermediate. 
Thanks to co-factor recycling system, the purified enzyme showed very promising results. 
The soluble expression of a novel ω-transaminase from a newly isolated halotolerant marine 
bacterium Virgibacillus pantothenticus was attained. Despite of several standard methodologies 
applied, the marine wild-type enzyme was total insoluble in E. coli host and it was satisfactorily 
solubilized by one single-point mutation, allowing the characterization of the new omega 
transaminase. The enzyme shows an interesting salt and solvent tolerance, in accordance to its origin 
and it results particularly active on some interesting building block molecules. 
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INTRODUCTION 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
BLUE FOR GREEN 
The marine ecosystem is the largest habitat on Earth, representing 70% of the surface of our planet 
and thus it is a critical driver of hydrologic cycle and climate system, important for commerce, 
transport, and tourism, a source of economically important resources, as well as new therapeutic 
compounds. Seas and oceans include the 
greatest extremes of temperature, light and 
pressure and habitats that still remain largely 
unexplored, understudied and 
underexploited in comparison with 
terrestrial ecosystems and organisms. 
Marine organisms are sources of natural 
bioactive substances with potential 
therapeutic activity, and they should also be 
valued as a source of genetic material to be 
explored by the bioprospecting industry1 
(fig. 1.1).  
 
 Fig. 1.1. A new term for an ancient process: bioprospecting refers to discovery and commercialization of new 
products starting from biological resources1.  
 
Only recently, indeed, the sea has been rediscovered as untapped source of novel biocatalysts and its 
extraordinary micro-biodiversity can offer new possibilities for conducting highly selective, enzyme-
catalysed reactions in industrial processing, laboratory analyses, and medical therapy1 (fig. 1.2). 
 
Fig. 1.2. Web of Knowledge Scientific hits 
containing “marine enzymes” (5528 total 
hits). 
 
 
 
 
 
Biocatalysts produced by marine microorganisms are naturally endowed with an excellent stability 
towards high salinity, as a consequence of different structural adjustments adopted to cope with high 
ionic strength conditions. Interestingly, adaptation to high salinity corresponds to an increased 
tolerance towards organic solvents, a requisite for many enzymes to be used as biocatalysts in organic 
chemistry2. From this point of view, marine habitats containing high salt concentrations, such a salt 
lake, the Dead Sea and deep hypersaline anoxic basins (DHABs), provide ideal locations to source 
novel marine biocatalysts3 (figure 1.3).  
  
 
 
 
 
 
 
 
 
 
 
Fig. 1.3. Biodiversity 
still represents an 
incredible resource and 
source of new and 
naturally high 
performing biocatalysts, 
thanks to a unique 
evolutionary pathway. 
 
 
 
The ability to tolerate high NaCl concentrations was investigated, since these extreme environments 
are usually characterised by high concentrations of this salt. In this condition, the cell is exposed to 
two different stimuli from the environment: osmotic and ionic stress. Typically, hyperosmotic stress 
causes immediate water outflow from the cell, reduces turgor pressure and consequently dehydrates 
the cytosol4. Ionic stress, on the other hand, results in an intake of ions (e.g. Na+) by the cell that 
increases intracellular ionic concentration leading damages to membranes and water discharge from 
the cell. One of the strategies adopted by marine microorganisms to counteract changes in turgor 
pressure is to lower the absorption of water and compensate with a build of compatible solutes that 
do not interfere with cell metabolism and maintaining internal concentration of Na+ at non-toxic 
levels5. Those microorganisms that can grow at high NaCl concentrations preferring to other 
conditions are defined as halophiles. Differently, the category of halotolerants is representative of 
those microorganisms that survive at different concentrations of NaCl and outweigh osmotic and 
saline stress but are not, however, in their optimal growth condition. Non-halophiles are all those 
microorganisms that do not overcome the stress due to the presence of salt at high concentrations and 
therefore are not able to perform their vital functions in this particular condition.  
 
Taking into account what deals with molecular adaptation of proteins that are stable and function at 
high salt concentration, understanding how these enzymes maintain their fold stable and avoid 
aggregation under harsh conditions is of great interest for biotechnological applications. Comparisons 
between the sequences of halophilic/non-halophilic homologous protein pairs indicated that Asp and 
Glu are significantly more frequent, while Lys, Ile and Leu are less frequent in halophilic proteins. 
Homologous halophilic and non-halophilic proteins have similar overall structure, secondary 
structure content, and number of residues involved in the formation of H-bonds. On the other hand, 
on the halophilic protein surface, a decrease of nonpolar residues and an increase of charged residues 
are observed. Particularly, halophilic adaptation correlates with an increase of Asp and Glu, 
compensated by a decrease of basic residues, mainly Lys, on protein surface6. Future studies will give 
further insights into the adaptation strategies to high salinity environment and will indicate strategies 
for rational protein engineering in order to improve enzyme industrial performance. 
 
BIOCATALYSIS 
Biocatalysis, assumed as applications of enzymes or whole cells for chemical synthesis, is an 
appealing technology for fine chemical, food and pharmaceutical industry for several reasons. 
The employment of biologic systems, such as whole cells or isolated enzymes, offers important 
advantages: 
 High efficiency – high turnover numbers; rates (108 – 1010). 
 Selectivity/specificity – chemo-, regio- and stereoselectivity. 
 Mild conditions – mild temperature and pH; atmospheric pressure. 
 Low energy consumption. 
 Not bound to their natural role (substrate tolerance). 
 Highly selective in complex mixtures (no side reactions). 
 Fewer by-products. 
 Biodegradable (natural bioproducts). 
 Can be overproduced. 
The excellent regio- and stereoselectivity of enzyme catalysts along with their ability to work under 
mild reaction conditions (thus protecting existing functionality within a molecule) enables 
transformations without the need for multiple protection and deprotection steps within a synthesis. 
Additionally, biocatalysis offers both economic and environmental advantages over chemocatalytic 
methods7,8.  
Enzymes are produced from 
inexpensive renewable resources 
and are themselves biodegradable, 
fulfilling the central tenants of 
Green Chemistry9 and sustainable 
development (fig. 1.4). 
 
  
 
 
 
 
 
 
 
 
 
Fig. 1.4. The Twelve Principles of 
Green Chemistry by Anastas and 
Warner (1998)9.  
Image from Compound of Interest® 
(http://www.compoundchem.com/2015/09/24/green-
chemistry/) . 
 
 
Besides the above-mentioned advantages, some drawbacks coming from the application of 
biocatalysis in chemistry must be recognized, such as:  
 Biocatalysts often show lower stability than conventional catalysts.  
 Development of industrial biocatalytic processes is usually much longer to establish. 
 Low number of commercially available biocatalysts. 
 Necessity of microbiological facilities if the biocatalyst is not a commercial enzyme. 
Most of these disadvantages might be overcome by modern techniques (screening, molecular biology, 
protein engineering, immobilization) able to furnish a much higher number of biocatalysts with 
improved performances. 
The whole process that sees the industrial application of a new enzyme usually begins with in vivo or 
in silico screening. The dominant strategy to discover new biocatalysts has varied from 
straightforward experimental assays for certain functions (experimental assays for functions) to 
deduction of protein functions from bioinformation data-bases (from sequence to function, from 
structure to function). After a biocatalyst characterization, process design has to fit with enzyme 
specifications and vice versa (fig.1. 5). 
 
Fig. 1.5. Flowchart of essential elements of 
biocatalyst discovery, characterization and 
improvement by protein engineering1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
As Bornscheuer et al. described10, we are living the third wave of biocatalysis progress. During the 
first wave of biocatalysis (fig. 1.6), which started more than a century ago, scientists recognized that 
components of living cells could be applied to useful chemical transformations (in contrast to the 
fermentation processes, which had been commonplace for millennia already). The main challenge for 
these applications is the limited stability of the biocatalyst, and such shortcomings were primarily 
overcome by immobilization of the enzyme, which also facilitated the reuse of the enzyme. During 
the second wave of biocatalysis, in the 1980s and 1990s, initial protein engineering technologies, 
typically structure based, extended the substrate range of enzymes to allow the synthesis of unusual 
synthetic intermediates. This change expanded biocatalysis to the manufacture of pharmaceutical 
intermediates and fine chemicals. Apart from stabilization, the challenges now included optimizing 
the biocatalyst for the non-natural substrates. The third, and present, wave of biocatalysis started with 
the work of Pim Stemmer and Frances Arnold in the mid and late 1990s. They pioneered molecular 
biology methods that rapidly and extensively modify biocatalysts via an in vitro version of Darwinian 
evolution. The methods are now commonly called directed evolution (see “Enzyme engineering” 
paragraph). 
 
Fig. 1.6. Based on protein structures (a) or homology models, rational design (b) approach is able to identify 
distinct point mutations, whereas for directed evolution experiments random mutagenesis (c) combined with 
screening is the starting point. Combining these methods makes it possible to create smaller, but smarter, 
libraries (d). The classical screening of enzymes by enrichment cultures (e) is now replaced by key motif 
database searches (f) to guide identification of novel enzymes or those with desired properties. Still in its 
infancy is the computational de novo design of enzymes (g)10. 
 
BIOCATALYTIC APPLICATIONS 
Despite the clear benefits of biocatalytic processes, the historical number of industrial applications 
has been modest, with a dramatic increase in the use of biocatalysis only occurring within the last two 
decades (fig. 1.7). 
 Fig. 1.7. Number of publications and patents discussing 
“pharmaceutical biocatalysis” for each 5-year period of the 
last 50 years. Metrics from Google Scholar 
 
 
 
 
 
The use of biocatalyst has acquired importance as a complement to conventional chemical techniques 
in various application fields. In particular, biocatalyst selectivity is important for obtaining 
biologically active molecules, whose stereochemistry affect their in vivo behaviour. The specific 
reactions that can be replaced with biocatalysis have been identified in the synthesis of biologically 
active molecules, including chiral amine preparation, stereo and regiospecific hydroxylation of 
complex molecules, and other redox reactions10,11.  
One of the first enzymatic applications in biologically active molecule synthesis was lipase resolution 
for the preparation of Naproxen in 1987 by Gu and co-workers12 (scheme 1.1). (+)-2-(6-Methoxy-2-
naphthyl) propionic acid has been prepared via enzymatic enantiospecific hydrolysis of (±)-
chloroethyl-2-(6-methoxy-2-naphthyl) propionate, catalyzed by the lipase of Candida cylindracea 
with E >100 (39% conversion; 98% e.e.). 
 
Scheme 1.1. Biocatalytic resolution of Naproxen intermediate by Candids cylindracea. 
Other examples of smart commercial enzyme applications are described for the antitumoral 
Capecitabine13 and anti-thrombotic Clopiogrel14 synthesis, both exploiting a serine protease catalysis. 
Alcalase CLEA enzyme is able to catalyse alcoholysis allowing the selective deprotection of primary 
acetyl ester of the N1-(2’, 3’, 5’-tri-O-acetyl-β-D-ribofuranosyl)-5-fluoro-N4-(n-pentyloxycarbonyl) 
cytosine and thus affording the corresponding 5’-hydroxyderivative, an advanced intermediate of 
capecitabine synthesis with a good yield (80% after purification). The (S)-2-chlorophenylglycine 
moiety is well recognized in the structure of (S)-clopidogrel. The enantiomerically pure chiral 
building block synthesis was performed via an enzyme-catalyzed resolution of (RS)-N-Boc-2-
chlorophenylglycine methylester. The high enantiomeric excess of the synthon was obtained by 
immobilized subtilisin (Alcalase CLEA). The simplicity of the process makes this pathway suitable 
for large-scale preparation. 
One of the most successful examples in the practical application of enzymes in the pharmaceutical 
industry is the anti-diabetic compound, sitagliptin15,16. Sitagliptin is a drug for type II diabetes that 
has been marketed under the trade name Januvia by Merck15. Researchers at Codexis and Merck 
engineered R-selective transaminase (R-ATA, ATA-117) from Arthrobacter sp. for the asymmetric 
amination of prositagliptin ketone. By applying a substrate walking, modeling, and mutation 
approach, they were able to overcome the limitation of the substrate's size for the enzyme. A 
combination of the further directed enzyme evolution and process engineering yielded a variant that 
converts 200 g/L of prositagliptin ketone into sitagliptin with enantio-purity higher than 99.95% even 
in the presence of 1 M i-PrNH2, 50% DMSO and 40 °C 
16 (scheme 1.2). Immobilization of engineered 
(R) selective-ATA enables the maintenance of the enzyme activity and stability in an organic solvent, 
simplifying the workup and allowing a repetitive use of the enzyme17.  
 
Scheme 1.2. Synthesis of sitaglipin from prositagliptin ketone using engineered (R)-selective ATA. 
Codexis recently developed a biocatalytic process for producing intermediates for blockbuster drugs 
such as atorvastatin, montelukast, duloxetine, phenylephrine, ezetimibe, and crizotinib based on 
stereo and regio-specific hydroxylation using keto-reductase (KRED) from Lactobacillus18,19.The 
anti-asthmatic drug, montelukast, was developed and marketed under the trade name Singulair by 
Merck20. Combined with a directed evolution and process optimization, the engineered KRED 
exhibits a high enantio-selectivity (> 99.9%) and stability even in the presence of ∼ 70% organic 
solvents at 45 °C (scheme 1.3). The biocatalytic process is currently operated on a > 200 kg scale 
substrate. The most intriguing point in KRED engineering is the increase of the enzyme stability even 
at a high organic solvent concentration and temperature. Because of the low solubility of the substrate 
in water, the high organic solvent concentration and temperature are necessary. Based on the 
correlation between the thermostability and solvent tolerance19, researchers at Codexis primarily 
screened enzyme mutants with increased thermal stability followed by a screening for solvent tolerant 
mutants19. 
 
Scheme 1.3. Regio-specific hydroxylation of key intermediate in synthesis of montelukast using engineered 
KRED20. 
In regards to whole cell biocatalysis, a high yielding bioprocess for 11-α hydroxylation of canrenone 
using Aspergillus ochraceus ATCC 18500 was described21. The optimization of the bioprocess 
involved both fermentation (for achieving highly active mycelium of A. ochraceus) and 
biotransformation with the aim to obtain 11-α hydroxylation with high selectivity and yield. A 
medium based on sucrose as C-source resulted particularly suitable for conversion of canrenone into 
the corresponding 11-hydroxy derivative, whereas the use of O2-enriched air and DMSO as a co-
solvent for increasing substrate solubility played a crucial role for obtaining high yields (>95%) of 
the desired product in high chemical purity starting from 30 mM (10.2 g/L) of substrate (scheme 1.4).  
 
Scheme 1.4. Conversion of canrenone into the corresponding 11-hydroxy derivative by Aspergillus 
ochraceus21. 
 
Another successful whole cell bioconversion led to the achievement of the enantiomerically pure 
advanced intermediate of the synthesis of (S)-pramipexole, a anti-Parkinson drug, showing the 
Baker’s yeast efficiency (figure 1.5). The use of readily available and inexpensive Saccharomyces 
cerevisiae, the easy preparation of the biotransformation substrate, and the simple steps required to 
accomplish the synthesis, make the method applicable to a preparative scale. 
This synthon, not yet described in the literature, was transformed through very simple steps into the 
desired dihydrochloride monohydrate derivative of (S)-pramipexole in 21% overall yield. A complete 
inversion of the configuration realized under the Mitsunobu22 conditions allowed the (S)-alcohol 
achievement. 
The (S)-alcohol obtained is a suitable substrate for dexpramipexole, the (R)-isomer of pramipexole, 
which is currently under investigation in the treatment of ALS (amyotrophic lateral sclerosis)23. 
 
Scheme 1.5. Enantioselective reduction of the keto-intermediate in pramipexole synthesis by Saccharomyces 
cerevisiae. 
 
BIOCATALYST FORM 
Biocatalysis can be performed by both whole cells and isolated enzymes. The type of bioconversion 
and enzyme features adress the choice. Whole cells allow the production of compounds also ensuring 
cofactor regeneration, with high regio- and stereoselectivity, under mild operational and environment-
friendly conditions. A limit of employing whole cells is sterile initial conditions and prevention of 
biological contamination. However, they are quite effective in multi-step reactions, they provide a 
protective environment to enzymes (e.g. in non-conventional media) and are signiﬁcantly cheaper to 
produce than free enzymes which require several isolation and puriﬁcation steps24,25. In one-step 
reactions, isolated enzymes should provide significant benefit when compared to whole cells as no 
side-reactions should occur and substrates do not have to be transported across membranes. The 
enzymes are able to catalyse more efficient reactions and under mild conditions, within a narrow 
range of pH and temperature. Furthermore, enzymes are able to maintain their activity under in vitro 
conditions and can catalyse reactions in conditions not suitable for cell growth. The use of pure 
enzymes in biocatalysis has several advantages such as the specificity for selected reactions, simple 
apparatus and procedures and better tolerance to co-solvents used to solubilise low-water soluble 
substrates26. However, enzyme isolation and purification can be quite expensive and time consuming, 
the addition of co-factors or their recycling may be required and, in general, it is more difficult to 
carry out reactions requiring more than one enzyme, contrarily to the use of whole microbial cells 
(table 1.1).  
 
BIOCATALYST FORM PROS CONS 
ISOLATED ENZYME any 
 simple apparatus, 
  simple work-up, 
 better productivity due 
to higher concentration 
tolerance 
 cofactor recycling 
necessary 
dissolved in water  high enzyme activities 
 side reaction possible,  
 lipophilic substrates 
insoluble,  
 work-up requires 
extraction 
suspended in organic solvents 
 easy to perform,  
 easy work-up,  
 lipophilic substrates 
soluble,  
 enzyme recovery easy 
 low activities 
immobilised  enzyme recovery easy 
 loss of activity during 
immobilisation 
WHOLE CELLS 
any 
 no cofactor recycling 
necessary 
 expensive equipment,  
 tedious work-up due to 
large volumes,  
 low productivity due to 
lower concentration 
tolerance,  
 low tolerant of organic 
solvents,  
 side reactions likely due 
to uncontrolled 
metabolism 
growing culture  higher activities 
 large biomass,  
 more by-products,  
 process control difficult 
resting cells 
 work-up easier,  
 fewer by-products 
 lower activities 
immobilised cells  cell re-use possible  lower activities 
 
Table 1.1. Pros and cons of using isolated enzymes and whole cell systems27. 
 
An important issue related to employing isolated enzyme is stability under relatively harsh conditions, 
such as high temperatures, pH and in the presence of solvents28. Limitations of biocatalysts can be 
overcome by integrating different techniques, such as genetic engineering, that allows the production 
of large quantities of enzymes at relatively low costs, biocatalyst immobilization, and suited reactor 
technology. Numerous molecular techniques have been developed to improve the activity or substrate 
specificity of an enzyme with a particular industrial application in mind. This includes random 
mutagenesis of a target gene followed by screening and rational protein engineering28,29 and directed 
evolution30,31. 
 
ENZYMES 
CLASSIFICATION 
The identity of the biocatalyst must be specified as per name of reaction type: EC number; strain 
deposit, GenBank sequence accession number.  
In according to International Union of Biochemistry and Molecular Biology, Enzyme commission 
(IUBMB EC) classification: 
 EC 1 oxidoreductases: oxygenation of C-H, C-C, C = C bonds; transfer of electrons.  
 EC 2 transferases: transfer of functional groups: aldehyde, ketone, acyl, phosphoryl, or methyl.  
 EC 3 hydrolases: formation/breakdown of esters, amides, lactones, lactams, epoxides, nitriles, 
anhydrides, glucosides, etc.  
 EC 4 lyases: removal or addition on C = C, C = N, C = O bonds.  
 EC 5 isomerases: racemization and epimerization.  
 EC 6 ligases: formation- cleavage of C-O, C-S, C-N, C-C bonds requiring ATP cleavage.  
 
KINETIC PARAMETERS 
The core kinetic parameters of an enzyme are Km and Vmax values, described by the Henry-Michaelis-
Menten equation32 that correlates the dependence of the reaction velocity (v) on the free substrate 
concentration (S). Briggs and Haldane (1925) provided a derivation of this equation introducing the 
steady-state approximation33 which assumes that the enzyme-substrate complex (ES) after initial 
formation reaches its climax and remains unchanged over the time the reaction is monitored.  
Km and Vmax are determined by directly plotting v over S (Michaelis- Menten plot) or more favourably 
by one of the linear transformations such as Lineweaver-Burk (1/v vs. 1/S), Hanes (S/v vs. S) or 
Eadie-Hofstee (v /S vs. v).  
Transformation of the Michaelis-Menten equation32 shows that Km specifies the substrate 
concentration where the reaction proceeds at half of Vmax. kcat, often referred to as the turnover 
number, can be calculated directly as the quotient of Vmax and the total enzyme concentration. 
Turnover numbers are normally reported as molecules product produced per molecules of enzyme 
per time (e.g. mol/mol s). Thus, if the same units are used for product and enzyme they eventually 
cancel each other and the unit for reporting kcat will be reciprocal time (e.g. s
−1). The kcat/Km ratio, 
originally referred to as “specificity34” or “performance35” constant and representing a second-order 
rate constant (M−1 s−1) is used as a measure for catalytic efficiency of an enzyme. In general, the 
higher kcat/Km the better is the enzymatic performance which can be used to compare enzymes or 
different substrates of one enzyme. 
 Fig. 1.7. Michaelis Menten Plot versus Lineweaver-Burk linear kinetic representation32. 
 
In a simple enzyme reaction over time one substrate is converted to yield one single product. This of 
course is not totally true since it often requires coenzymes (e.g. NAD(P)H for oxidoreductases) or co- 
substrates (e.g. water for hydrolases) or, in the case of lyases (synthases), yields, technically speaking, 
two products or converts two products into one substrate. To kinetically describe these kinds of 
reactions it is important to define one speed-limiting factor which could be substrate, co- substrate, 
etc., at a time and supply the respective others in excess. During the enzymatic assay, substrate 
concentration is much higher than enzyme concentration remaining virtually unchanged, and product 
accumulation is linear and there is no back reaction into substrate. Substrate concentrations are crucial 
and should be in the range of 0.1 to 10 times Km which for unknown enzymes often has to be 
determined using trial approaches (fig. 1.8).  
 
 
 
 
Fig. 1.8. Progress curve for an enzyme reaction. The 
slope in the initial rate period is the initial rate of 
reaction v. The Michaelis-Menten equation describes 
how this slope varies with the concentration of 
substrate. 
 
 
In an enzymatic assay, one of the key parameters to check is the initial rate measured as specific 
activity (SA). SA gives a measure of enzyme processivity, at a specific (usually saturating) substrate 
concentration, and is usually constant for a pure enzyme. It is conventionally expressed in Units (U) 
as µmol min−1 mg−1 or in katal kg−1. Enzyme Unit (U) is defined as the amount able to catalyse the 
transformation of 1 micromole of the substrate per minute under standard conditions. Turnover 
number, on the other hand, is dimensionless referring to the ratio of number of moles of product per 
mole of catalyst used over the reaction period. On enzyme assays, depending on what methods are 
being used (e.g. spectrophotometry or measurement of fluorescence using a fluorometer), it may be 
critical to find the optimum conditions of pH, temperature, buffer concentrations (ionic strength), 
metal or cofactor requirements. Importantly, the enzyme concentration used has to be appropriate 
since accurate determination of the enzyme’s SA requires the presence of excess amounts of 
substrate(s) and possible co-substrate(s).  
 
SPECIFICITY AND SELECTIVITY 
One of the characteristics of an enzymatic catalysis is the specificity for substrate(s) and reactions. 
Enzymes are generally highly specific for one reaction type, but promiscuous activities can be found 
in nature or can be introduced into an enzyme by protein engineering. Specificity and selectivity are 
often used as synonyms to describe the ability of an enzyme to distinguish between substrates; more 
correctly, substrate specificity refers to a reaction where one (and only one) substrate can react, 
whereas substrate selectivity describes a reaction where one substrate is preferentially transformed 
over others. Therefore, the term enantioselectivity is preferentially used when the substrates are 
enantiomers. Enzymes also exhibit chemoselectivity for similar functional group, and regioselectivity 
for analogous functional groups with different chemical neighbourhood. 
To better characterize the stereoselective properties of an enzyme and thus to quantitatively assess its 
potential for kinetic resolution36 the dimensionless enantiomeric ratio (E)36 was introduced. It is 
expressed as the quotient of the second-order rate constants (kcat/Km) R and (kcat/Km) S. This is a 
measure for the ‘selectivity’ of an enzymatic resolution37. E values can be experimentally calculated 
by measuring the enantiomeric excess (ee) of either the residual substrate or the corresponding 
product at the specific degree of conversion (C). To obtain accurate E values, the general rule is to 
stop the reaction at about 50% conversion.  
 
STABILITY 
In an industrial setting, stability of a biocatalyst is one of the most important characteristics. Even the 
most active enzyme will be practically useless if it does not maintain its activity over the envisioned 
treatment or production process time. For process development, the fundamental question is whether 
the enzyme has to be designed to meet an existing protocol or whether the process can be designed 
to adapt to the enzyme’s properties. One can distinguish between several forms of enzyme stability, 
such as chemical stability (e.g. the influence of pH, salt or solvent concentration), thermodynamic 
stability (e.g. reversible unfolding of the protein structure due to increasing temperature) and kinetic 
stability (describing the time the enzyme remains active before undergoing irreversible 
denaturation)28,38. Enzyme stability studies, however, are often performed under laboratory 
conditions (e.g. in a simple buffer) and thus, although giving some insight, they only have limited 
value for assessing the enzyme’s bioprocess suitability. Under process conditions, enzyme behaviour 
can be very different with substrate(s), accumulating product(s) and possible solvents modulating its 
activity in either way: positive (protection) or negative (destabilization)39.It should be noted that 
enzyme stability often depends on the concentration that it was assayed, thus adding another variable.  
 
ENZYME ENGINEERING 
Enzymes were optimized by Darwinian evolution over millions of years to catalyse reactions while 
ensuring high substrate specificity, as well as exquisite enantioselectivity and stereoselectivity. 
However, there are often significant discrepancies between an enzyme’s function in nature and the 
specific requirements for ex vivo applications envisioned by scientists and engineers.  
The modification of enzymes for adaptation to the environment in a chemical process is often 
considered necessary, for which many strategies have been developed40. Frequently the compounds 
in the process are poor substrates, the enantioselectivity may be insufficient, or a more heat stable or 
co-solvent tolerable enzyme is desired. By using an experimentally determined structure of the 
enzyme (determined by X-ray crystallography or NMR) the enzyme engineer can locate specific 
amino acid residues suitable for mutation. This is called rational design; arguably, the amount of 
knowledge which is available regarding the function of a given enzyme dictates the likelihood of 
success with this strategy. When such attempts are unsuccessful, or a structure is unavailable, the 
amino acid chain can be altered in a randomised fashion and a library of mutants can be screened for 
the desired properties. An improved clone can be further randomised and a new library can be 
screened. The iterative process is repeated for the potential discovery of the required enzyme. This 
strategy is called directed evolution41–45. Further, to increase the probability of finding improved 
variants, semi-rational40 approaches have been devised, such as CASTing46,47 and saturation 
mutagenesis. The more recent scientific publications involving enzyme engineering contain examples 
of rational and semi-rational approaches with a higher frequency than in the past. This phase in 
biocatalytic progress was called “third wave” by Bornscheuer10 as we previously reported. The 
method advancements, increased understanding of function and examples of successful enzyme 
variants have made researchers less inclined to resorting to directed evolution, which most often 
involves a tedious screening procedure. The choice of method is usually not straightforward, and 
remains a challenge for the enzyme engineering48.  
 
  
 
For what concerns the enzyme activities taken into account, keto-reductase and transaminase 
activities were the main biocatalytic strategies investigated. 
 
KETO-REDUCTASES 
Ketoreductases (KREDs) are enzymes useful for enantiomeric preparation of chiral alcohols from 
ketones, ketoacids and ketoesters19 (scheme 1.6).  
 
 
Scheme 1.6. Simplified catalysis by KRED. 
 
KREDs can induce an asymmetric attack of the hydride with total or prevalent formation of one of 
the two enantiomers. The cofactors (mostly NADH or NADPH) provide the hydride ion giving rise 
to the reduction of the substrate. Yeasts are usually employed for synthetic purposes with main 
application in stereoselective reduction of ketones affording optically pure secondary alcohols49–52. 
In particular, marine yeasts have already been investigated for the production of pharmaceutical and 
enzymatic products, such as astaxanthin, siderophore, riboflavin, inulinase and amylases. Yet, the 
commercial application of marine yeasts is still limited. The current research, however, indicates the 
promising features of the marine yeasts for the potential industrial application and their superiority 
over the terrestrial ones in certain field. More direct comparison studies should be carried out to give 
further evidence on the advantages of marine yeasts over terrestrial yeasts53, as explained in the 
second chapter. 
 
TRANSAMINASES 
 
Transaminases, also called amino transaminase (ATA), are enzymes capable of the enantioselective 
transfer of an amino group from the amino donor to the acceptor substrate. The α-ATAs are able to 
operate on the amino moieties of the α-carbon of amino acids, while the ω-ATAs mainly accept as 
substrates donors with amines distal to the carboxyl moiety, as well as other amine donors and their 
respective non-keto acid acceptors (scheme 1.7).  
 Scheme 1.7. Simplified catalysis by ω-ATA. 
Combining ATAs with other enzymatic or chemical routes has been demonstrated to be a smart 
method for practical applications, particularly in regard to shortening the reaction routes, avoiding 
protecting steps, reducing chemical waste and achieving a high atom-efficiency. This makes these 
enzymes useful for synthesis of chiral amines, which are of high importance as building blocks for 
production of optically pure amino synthons in pharmaceutical like sitagliptin16, ethambutol54, 
imagabalin55, norephedrine and pseudoephedrine56, food and cosmetic additives57, agrochemical and 
material industries. The development of protein engineering has tried to answer to this need and it is 
achieving remarkable progresses through random and rational mutagenesis approach but some issues 
need to be completely clarify yet. The current trend in the research field is directing to the 
identification and designing of new ω-transaminases with defined substrate selectivity and capable of 
adapting to the uncommon catalytic conditions of industrial processes. The issue will be widely 
discussed in the following chapters.  
 
TARGET MOLECULES 
The range of molecules evaluated in this PhD project was selected in order to obtain asymmetric 
catalysis or kinetic resolution providing chiral building blocks aimed at the synthesis of biologically 
active molecules with a solid industrial appeal. 
PRAMIPEXOLE 
One of the target molecules investigated in this project is pramipexole. A recent example is the 
preparation58 of an optically pure new intermediate of (R)- or (S)-pramipexole; this thiazole derivative 
is endowed with anti-Parkinson activity59–61 if its stereocenter is in the (S)-configuration, while the 
(R)-isomer is under investigation for the treatment of ALS (amyotrophic lateral sclerosis) 23 (fig. 1.9).  
 Fig. 1.9. Pramipexole enantiomers could have different applications as therapeutics. 
 
Numerous new synthetic pathways were recently developed and patented62–64. The strategy which 
this experimental work is based on involves a biocataytic keto-reduction step in order to obtain an 
optically pure alcohol, intermediate in this new synthetic method58(scheme 1.8).   
 
Scheme 1.8. This synthetic pathway based on the previous work by Ferraboschi et al.58 combines chemical 
and biocatalytic steps. 
MIRAPEX® by Boehringer Ingelheim® is the most common drug formulation containing as active 
substance (S)-pramipexole dihydrochloride. Currently, also the generic drug is available on the 
market. For what concerns anti-Parkinson drug distribution, the global prevalence in 2012 was 
approximately 2.18 million cases world-wide; this resulted in $3.56 billion in global market sales of 
therapies, including $1.15 billion in the U.S. market. Through advances in technology and drug 
development, the Parkinson treatment’s market in 2022 is expected to yield $5.26 billion in global 
market sales, with $2.33 billion from the U.S. market65.  
Because of the increasing spread of the disease, the global market of anti-Parkinson drugs is 
expanding and, consequently, Mirapex®, representing one of the most prescribed therapy, is getting 
an important slice of this market66. 
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AIM OF THE WORK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
This PhD project focuses on the identification, isolation and characterization of new biocatalysts able 
to generate biologically active molecules with significant enantioselectivity. Through screening, we 
identified marine strains, from MaCuMBA (Marine Culturable Microorganism for Biotechnological 
Applications) and BIODEEP (Biotechnologies form the deep) European project collections, which 
show a marked enantioselectivity on intermediates of molecules of biological interest. Once identified 
the strains and optimised the biotransformation conditions with whole cells, the most promising 
enzyme was cloned and overexpressed in a suitable host. After biochemical characterization of the 
biocatalyst, the final challenge was the rational engineering of the protein to improve its biocatalytic 
features. 
Biotransformation substrate range included pramipexole, as the main target, but it also embraced 
other common building blocks for synthetic industrial preparation. 
 
 
 
The following chapters are organised according to what reported below. 
 
WHOLE CELL SCREENING  
MARINE YEASTS ACTIVITY 
Due to cofactor requirement, keto-reductase biotransformations are more efficiently carried out in 
whole cell system. The stereoselective reduction of structurally different ketones using halo-tolerant 
marine yeasts was studied using cells grown and bio-converted in seawater.  
For what concerns pramipexole, the goal was to find a marine yeast able to reduce the ketone 
intermediate with an opposite stereochemical outcome in comparison with Saccharomyces 
cerevisiae. In order to compare biocatalytic performances, also non-marine yeasts (Rhodotorulae 
species) were tested on pramipexole intermediates. 
MARINE BACTERIA ACTIVITY  
Taking into account pramipexole, firstly keto-reduction potential of thirty-three marine bacterium 
species was checked and afterwards the possibility to convert this substrate directly into the optically 
pure amine was investigated: marine bacteria were screened to identify transaminase activity. 
According to transaminase biocatalytic applications, where cofactor recycling is not needed, the aim 
in this case was to express and employ a recombinant enzyme. 
RECOMBINANT ENZYME SCREENING 
KETO-REDUCTASE ACTIVITY 
A recombinant non-marine ketoreductase from Pichia glucozyma (KRED1-Pglu) was used for the 
enantioselective reduction of various cyclic ketones including pramipexole ketone intermediate. 
Thanks to a co-factor recycling system, the purified enzyme showed very promising results. 
ESTERASE AND LIPASE ACTIVITY 
Other enzymatic activities were investigated in order to achieve optically pure intermediates for the 
preparation of both pramipexole enantiomers. Ten of the most common commercial lipases and one 
new recombinant esterase from Bacillus coagulans were tested on pramipexole ester intermediates. 
MARINE ω-TRANSAMINASE ACTIVITY 
Chromobacterium violaceum and Halomonas elongata ω-transaminases were screened for 
biocatalityc conversion of pramipexole intermediates. 
VIRGIBACILLUS PANTOTHENTICUS ω-TRANSAMINASE 
Trying to improve the pramipexole synthetic pathway by a biocatalytic approach, the promising 
marine bacteria Virgibacillus pantothenticus was selected and a new ω-TA was cloned, overexpressed 
and characterised. 
 
  
 
 
 
 
 
 
 
WHOLE CELL SCREENING - MARINE YEASTS 
 
 
 
  
In this chapter, a screening for keto-reductase activity and halotolerance on a heterogeneous group of 
marine yeasts, recently isolated and characterized1,2, will be described. 
BACKGROUND 
MARINE YEASTS 
As it was deeply discussed in the previous chapter, through million years of evolution, marine 
microorganisms belonging to the three kingdoms of life Bacteria, Archaea and Eukarya, have 
developed unique metabolic and physiological abilities in order to respond to the most extreme 
stresses3.  
Specifically, for this experimental project, different strains of marine yeasts belonging to 
Basidiomycota and Ascomycota phyla have been studied and screened with biocatalytic purposes. 
The microorganisms were provided by MaCuMBA European research project (Marine 
Microorganisms: Cultivation Methods for Improving their Biotechnological Applications, FP7, Grant 
Agreement 311975, Brussels, Belgium), which explored unique marine ecosystems focusing on 
isolation and setting up culturing methods for marine microorganisms. From the biocatalytic point of 
view this collection offers new opportunities for studying significant enzymatic activities. The yeast 
strains were isolated at different depths of the Pacific and Atlantic Ocean seafloor and in particular 
from deep-subseafloor sediments and hydrothermal vents. These unique environments are 
characterized by a variety of chemical and physical properties including low availability of nutrients, 
exposure to high saline concentrations, high hydrostatic pressure, extreme pH and temperature 
changes.  
The strains originating from the sediments of seafloor were isolated at different depths from the 
Canterbury Basin in New Zealand (44° 56 26.62 "S, 172 ° 1 36.30" E)2.  
For what concerns hydrothermal springs, the samples were collected in rifts characterized by the 
presence of faults, magma, basalt and volcanic rocks. Water infiltration allows the dissolution of 
minerals in the springs. The hot winds, "black smokers"(fig. 2.1), can reach a temperature of 270-380 
°C4.They are characterized by the lack of dissolved oxygen, high acidity (pH 2 or 3), high 
concentration of electron donor molecules (e.g. reduced compounds such as methane and hydrogen 
sulphide) and the presence of heavy metals5. Continuous mixing with cold ocean water (2 to 4 °C), 
rich in electron acceptor molecules, creates a chemical imbalance that is a source of energy for 
microorganisms that control the speed of redox reactions6. 
 Fig. 2.1. “Black smokers” from hydrothermal vents on the sea floor. 
KETO-REDUCTASE 
The oxidoreductases have been classified, according to the primary sequence and secondary structure 
folding into four main superfamilies: 
 Medium-chain Dehydrogenases/Reductases (MDRs) participate in numerous oxidation 
reactions of alcohols, detoxification of aldehydes and alcohols and they are active in the 
metabolism of bile acids. Other components of this family are cinnamyl alcohol 
dehydrogenase (CAD), polyhydrodehydrogenase (PHD) and quinone oxidoreductase (QOR). 
All MDR enzymes use NADH and NAD(P)H as cofactor and not all but several members of 
this family possess a zinc ion for catalytic activity in the active site7.  
 Flavin mononucleotide dependent reductases, also known as the old yellow enzymes (OYE) 
in relation to the colour associated with flavin cofactor, are exploited for stereoselective 
biorheduction of double bonds C = C8. 
 Aldo-Keto Reductases (AKRs) are a superfamily of dependent NADP(H) oxidoreductases 
that can perform their action on a wide variety of both endogenous and exogenous substrates. 
These enzymes are made up of monomeric proteins of about 320 amino acid residues of length 
with an 8-barrel ad (α / β) structure. Their active site contains a conserved catalytic tetrade 
composed of Tyr, His, Asp and Lys. They are located in most living organisms and metabolize 
steroids, sugars, prostaglandins, polycyclic aromatic hydrocarbons, and a large variety of non-
steroidal aldehydes and ketones9.  
 Short chain dehydrogenases/reductases (SDRs) are a superfamily that consists of enzymes of 
250 - 300 amino acid residues. Their functionality is independent of metal cofactors and its 
members are easily distinguishable from the superfamily of alcohol medium and long chain 
dehydrogenases. They are in some cases membrane proteins mostly soluble homodimers or 
homotetramers with the classic βαβ folding pattern of Rossman able to link both NADH and 
NAD(P)H cofactors. SDRs include a large and highly diverging superfamily of enzymes with 
over 3,000 known forms (including varieties of species), preserving a gender identity of 15-
30% and covering a broad spectrum of activities on substrates such as alcohols, sugars, 
steroids, prostaglandins, aromatic and xenobiotic compounds10,11. 
 
Keto-reductases (KREDs) were originally classified, based on their functionality, in the superfamily 
of AKRs. Subsequently, with the discovery of some homologues amino acid residues of SDR 
superfamily they were included in this superfamily. KREDs are structurally characterized by the 
typical domain involved in binding to the cofactor, called Rossmann-fold, with a GlyXXXGlyXGly 
preserved sequence in the N-terminal of the enzyme. Another preserved amino acid which constitutes 
the active site of some of these enzymes is the Tyr at position 194 which is part of the TyrXXXLys 
common sequence of SDRs.  
KREDs are, indeed, enzymes useful for chemo, regio, and stereoselective reductions/oxidations, 
being particularly useful for  the synthesis of chiral alcohols from ketones, keto-acids and keto-esters. 
They are also able to catalyse the reaction of reduction of numerous aldehydes and more generally 
catalyse a series of stereoselective reactions on a wide range of substrates: 
 reduction of carbonyl groups;  
 oxidation of secondary alcohols; 
 reduction of 2-substituted-3-ketoesters. 
KREDs also usually exhibit high stereoselectivity, in fact they are able to act on molecules with two 
prostereogenic centers reducing only one with regioselectivity12. 
 
DH CATALYTIC MECHANISM 
The catalytic mechanism of carbonyl-reductase indicated by the generic term of dehydrogenase (DH) 
is closely related to two nicotinamide-deriving co-factor: NAD+ and NADP+. DHs transfer electrons 
from the substrate to these electron carriers that are reduced and considered oxidizers of the substrate, 
in this way the cofactor will require its regeneration to continue the reduction of other substrate 
molecules (scheme 2.1). 
 
Scheme 2.1. Mechanism of an aldehyde dehydrogenase, note the use of NAD+ as an electron acceptor13. 
The configuration of the alcohol obtained as product generally follows an empirical rule determined 
by Prelog, even if the catalytic mechanisms to date are still not entirely clear. In the early 1960s, 
Prelog proposed a simple model to predict the stereochemistry of the products based on the steric 
requirements of the substrates. 
 
Scheme 2.2. Stereochemistry of the hydride transfer from NAD(P)H to the carbonyl carbon on a ketone substrate. 
ADPR = adenosine diphosphoribose, R1 is more sterically hindered and has higher Cahn–Ingold–Prelog priority 
than R2  14. 
In the asymmetric reduction of a prochiral ketone, there are four possible pathways to deliver the 
hydride from NAD(P)H, as shown in scheme 2.2. The pro-(R) or pro-(S)-hydride can attack from the 
re face of a prochiral ketone, to produce the (S)-alcohol, according to Prelog's Rule, or it can also 
attack from the si face of a ketone to produce the (R)-alcohol. (It should be noted that sometimes the 
products have opposite assignments because the small substituent, if alkenyl or alkynyl, has a higher 
Cahn–Ingold–Prelog priority than the larger alkyl one). The majority of commercially available 
ADHs, like yeast ADH (YADH), horse liver ADH (HLADH), and Thermoanaerobium brockii ADH 
(TbADH), fall in the first category (i.e. they deliver the pro-(R)-hydride from the re face of a prochiral 
ketone). A few ADHs are known to have anti-Prelog stereopreference; however, very few of them 
are commercially available, one of which is Lactobacillus kefir ADH (LkADH)15. 
A limit of employing recombinant ADHs is the regeneration of cofactor. These compounds are very 
expensive, unstable and consumed in a stoichiometric amount. For the development   of   an industrial 
application of oxidoreductases, this problem has been overcome by the in situ recycling  techniques 
allowing the  use of catalytic amounts of these compounds. 
PROJECT AIM 
Due to cofactor requirement, keto-reductase biotransformations are more efficiently carried out in 
whole cell system. The stereoselective reduction of structurally different ketones using halotolerant 
marine yeasts was studied using cells grown and bioconverted in seawater.  
 
For what concerns pramipexole, the goal was to find a marine yeast able to reduce the ketone 
intermediate with an opposite stereochemical outcome in comparison with Saccharomyces cerevisiae 
(scheme 2.3).  
 
Scheme 2.3. Steroeselective reduction of keto-intermediate of pramipexole by yeasts. 
 
RESULTS AND DISCUSSION 
KETO-REDUCTASE SCREENING 
Enzymatic activity screening was carried out on a first more homogeneous group of marine yeasts 
including genera with already known reductive potentials16–18.  
Eight strains of Meyerozyma guilliermondii and twelve strains of Rhodotorula mucilaginosa isolated 
previously from different deep-sub-seafloor sediment depths at Canterbury Basin (New Zealand)2 
were grown in a liquid YPD (yeast extract, peptone, D-glucose) prepared with purified freshwater or 
micro-filtered seawater. After 48h the optical density was checked and three strains appeared to be 
particularly halotolerant showing a similar production of biomass in freshwater- and in seawater-
based media: Meyerozyma guilliermondii UBOCC-A-214008, Rhodotorula mucilaginosa UBOCC-
A-214025 and Rhodotorula mucilaginosa UBOCC-A-214036. Therefore, the keto-reductase activity 
of these strains was checked towards structurally different substrates. 
ARYLMETHYLKETONES 
 
 
Scheme 2.4. Arylmethylketones employed as substrate. 
The biocatalytic potential of these three marine yeasts was first tested on arylmethylketones (1 a–d), 
substrates of choice to test stereoselective keto-reductase activity. 
 Table 2.1. Reduction of arylmethylketones 1 a–d (10 mm) with marine yeasts. 
 
No activity was found towards acetophenone 1 a with strains of Meyerozyma guilliermondii, whereas 
the selected strains of Rhodotorula mucilaginosa gave (S)-1-phenylethanol with high yield and 
Entry Strain Medium Substrate Yield [%] ee [%] t [h] 
 
1 M. guilliermondii UBOCC-A-214008 freshwater 1 a <5 n.d. 48 
2 M. guilliermondii UBOCC-A-214008 seawater 1 a <5 n.d. 48 
3 M. guilliermondii UBOCC-A-214008 freshwater 1 b 90 97 24 
4 M. guilliermondii UBOCC-A-214008 seawater 1 b 65 88 48 
5 M. guilliermondii UBOCC-A-214008 freshwater 1 c <5 n.d. 48 
6 M. guilliermondii UBOCC-A-214008 seawater 1 c <5 n.d. 48 
7 M. guilliermondii UBOCC-A-214008 freshwater 1 d <5 n.d. 48 
8 M. guilliermondii UBOCC-A-214008 seawater 1 d <5 n.d. 48 
9 R. mucilaginosa UBOCC-A-214025 freshwater 1 a > 97 > 98 8 
10 R. mucilaginosa UBOCC-A-214025 seawater 1 a > 97 > 98 8 
11 R. mucilaginosa UBOCC-A-214025 freshwater 1 b <5 n.d. 48 
12 R. mucilaginosa UBOCC-A-214025 seawater 1 b <5 n.d. 48 
13 R. mucilaginosa UBOCC-A-214025 freshwater 1 c 72 > 98 24 
14 R. mucilaginosa UBOCC-A-214025 seawater 1 c 60 > 98 24 
15 R. mucilaginosa UBOCC-A-214025 freshwater 1 d 94 > 98 3 
16 R. mucilaginosa UBOCC-A-214025 seawater 1 d 87 > 98 3 
17 R. mucilaginosa UBOCC-A-214036 freshwater 1 a > 97 > 98 8 
18 R. mucilaginosa UBOCC-A-214036 seawater 1 a > 97 > 98 8 
19 R. mucilaginosa UBOCC-A-214036 freshwater 1 b <5 n.d. 48 
20 R. mucilaginosa UBOCC-A-214036 seawater 1 b <5 n.d. 48 
21 R. mucilaginosa UBOCC-A-214036 freshwater 1 c 72 > 98 48 
22 R. mucilaginosa UBOCC-A-214036 seawater 1 c 61 > 98 48 
23 R. mucilaginosa UBOCC-A-214036 freshwater 1 d 80 >98 3 
24 R. mucilaginosa UBOCC-A-214036 seawater 1 d 72 >98 3 
enantioselectivity. The biotransformation of 1 a occurred with no significant differences between 
freshwater or seawater. The two strains of Rhodotorula mucilaginosa were not active for 1 b but 
reduced 1 c and 1 d to a different extent. 1-(Furan-2-yl)ethanone (1 d) was reduced enantioselectively 
with high yields and high rates by the two strains of R. mucilaginosa both in freshwater and seawater. 
With 1 c, a higher efficiency in the reduction to enantiopure (S)-1-(thiophen-2-yl)ethanol (2 c) could 
be observed in freshwater. 
From the point of view of stereoselectivity, all the tested strains gave ketone reduction that followed 
the so-called Prelog rule with the formation of the alcohols with an S configuration. Overall, bio-
processes performed entirely in seawater gave good results, although a slightly poorer activity was 
generally observed than for that in freshwater. 
β - KETONITRILES 
 
Scheme 2.5. β-Ketonitriles employed as substrate. 
Asymmetric β-hydroxy nitriles are valuable chiral intermediates for the synthesis of a number of 
biologically active compounds; hence, we evaluated the reduction of 3-oxo-3-arylpropanenitriles 1 e–
g with marine yeasts in seawater. The biocatalytic reduction of β-ketonitriles has been explored using 
both isolated enzymes (which need systems for co-factor regeneration)19–23 and whole cells24; the 
latter approach has the advantage of that it can supply co-factors and systems naturally for their 
regeneration but it is often hampered by the occurrence of competitive alkylation24, which limits the 
preparative scope of these biotransformations.  
Entry Strain Substrate Yield [%] ee [%] 
1 R. mucilaginosa UBOCC-A-214025 1 e 93 >98 
2 R. mucilaginosa UBOCC-A-214025 1 f 85 >98 
3 R. mucilaginosa UBOCC-A-214025 1 g 88 >98 
4 R. mucilaginosa UBOCC-A-214036 1 e 92 >98 
5 R. mucilaginosa UBOCC-A-214036 1 f 93 >98 
6 R. mucilaginosa UBOCC-A-214036 1 g 79 >98 
Table 2.2. Reduction of β-ketonitriles 1 e–g (10 mm) with R. mucilaginosa grown in YPD-seawater medium. 
 
Two distinct behaviours were observed for the yeasts employed: strains of R. mucilaginosa gave the 
reduction products 2 e–g (table 2.2) as the only detectable compounds obtained by biotransformation 
with a high enantioselectivity to afford optically pure (S)-2 e–g. The yields and enantioselectivity 
obtained using the two strains are remarkable; the high selectivity (both because of the avoidance of 
by-products and enantioselectivity) in the reduction of aromatic β-ketonitriles with whole cells of 
yeasts was observed previously mostly with strains that belong to the genus Rhodotorula. However, 
M. guilliermondii UBOCC-A-214008 gave the 2-ethylketones 3 e–g as major products and traces of 
(S)-3-hydroxy-3-arylpropanenitriles 2 e–g. 2-Ethylketones resulted from non-enzymatic aldol 
condensation between aromatic β-ketonitriles and acetaldehyde (formed by the yeasts in the presence 
of glucose) followed by the reduction of activated C=C by enoate reductases (Scheme 2.5)25. This 
different behaviour seems to indicate the presence of pyruvate decarboxylase activity in M. 
guillermondii, which is lacking in R. mucilaginosa strains. The biotransformations with cells grown 
and used in freshwater gave similar results (data not shown). 
 
Scheme 2.6. Formation of 2-benzoylbutanenitrile (3 e) from 3-oxo-3-phenylpropanenitrile (1 e) in the presence of 
glucose26. 
STEROIDAL ETHYL SECODIONE 
 
Scheme 2.7. Bioconversion of steroidal ethyl secodione. 
 To further explore the substrate range accepted by ketoreductases of the selected marine yeasts, 
steroidal ethyl secodione derivative 1 h was tested as a substrate (scheme 2.7 and table 2.3). The 
stereoselective reduction of the diketone 1 h provides the key chiral precursor for the synthesis of a 
number of hormonal contraceptives (i.e., desogestrel, norgestrel, gestodene)23. The biotransformation 
of 1 h is complicated by the low solubility of the substrate in water; recently, we reported the use of 
different biocatalysts for the stereoselective mono-reduction of 1 h and noticed that the use of EtOH 
(both to increase solubility and favour co-factor regeneration) was beneficial for biotransformations 
with whole microbial cells27. Thus, the reduction of 1 h with marine yeasts was performed in the 
presence of different amounts of EtOH (1–5 %), and the best results were found with an EtOH 
concentration of 3.5 %. 
 
 
 
Table 2.3. Reduction of ethyl secodione 1 h (10 mM) with marine yeasts grown in YPD-seawater medium. 
The biotransformation of 1 h in seawater occurred only with R. mucilaginosa; the reduction of the 
carbonyl occurred with high enantioselectivity to form a mixture of the stereoisomers (13S, 17S)-2 h 
and (13R, 17S)-3 h with a different stereoselectivity that depended on the strain employed. Reduction 
with R. mucilaginosa UBOCC-A-214036 was highly stereoselective and furnished (13S, 17S)-2 h as 
the main product. 
PRAMIPEXOLE KETO INTERMEDIATE 
 
Scopo: sintesi R per S pramipex 
 
Entry Strain Yield [%] 2 h/3 h 
1 M. guilliermondii UBOCC-A-214008 <5 n.d. 
2 R. mucilaginosa UBOCC-A-214025 97 63/37 
3 R. mucilaginosa UBOCC-A-214036 96 92/8 
Scheme 2.8. Reduction of keto intermediate of pramipexole. 
Finally, the reduction of the pro-chiral bicyclic ketone 1 i was evaluated (table 2.4). Enantiomerically 
pure 2-acetylamino-6-hydroxy-4,5,6,7-tetrahydrobenzothiazole (2 i) is the synthon of the anti-
Parkinson (S)-pramipexole28. An initial screening with growing cells after 24h had led to an 
interesting result by R. mucilaginosa UBOCC-A-214025. 
Microorganisms UBOCC number Conversion e.e. Configuration 
Meyerozyma guilliermondii strain UBOCC-A-214022 100% 7,5% R 
Meyerozyma guilliermondii strain UBOCC-A-214008 100% 5% R 
Meyerozyma guilliermondii strain UBOCC-A-214007 100% 1,3% R 
Rhodotorula mucilaginosa strain UBOCC-A-214045 100% 40% S 
Meyerozyma guilliermondii strain UBOCC-A-214013 100% 2% R 
Meyerozyma guilliermondii strain UBOCC-A-214014 100% 1% R 
Not sequenced UBOCC-A-214004 84% 26% R 
Rhodotorula mucilaginosa strain UBOCC-A-214143 100% 45% S 
Rhodotorula mucilaginosa strain UBOCC-A-214015 100% 0,15% S 
Rhodotorula mucilaginosa strain UBOCC-A-214039 100% 42% S 
Rhodotorula mucilaginosa strain UBOCC-A-214049 100% 62% S 
Rhodotorula mucilaginosa strain UBOCC-A-214040 98% 50% S 
Rhodotorula mucilaginosa strain UBOCC-A-214034 100% 56% S 
Rhodotorula mucilaginosa strain UBOCC-A-214025 100% 64% S 
Rhodotorula mucilaginosa strain UBOCC-A-214046 100% 48% S 
Rhodotorula mucilaginosa strain UBOCC-A-214036 100% 38% S 
Rhodotorula mucilaginosa strain UBOCC-A-214051 100% 48% S 
Rhodotorula mucilaginosa strain UBOCC-A-214043 100% 50% S 
Rhodotorula mucilaginosa strain UBOCC-A-214006 100% 50% S 
Rhodotorula mucilaginosa strain UBOCC-A-214026 100% 49% S 
 
Table 2.4. Reduction of ketone 1 i (10 mm) with marine yeasts grown in YPD-seawater medium after 24 h. 
All the tested strains gave a high conversion of 1 i into the desired alcohol with the predominant 
formation of (S)-2 i; R. mucilaginosa UBOCC-A-214025 gave the highest ee (64 %), whereas 
reduction with M. guilliermondii was not enantioselective. The relatively low enantioselectivity 
observed in the reduction of 1 i performed under standard conditions led us to investigate the effect 
of biotransformation conditions in order to improve enantioselectivity. The best results were observed 
using 40 mgdry weight mL−1 of cells, 25 mM substrate in the presence of 7 % iPrOH at 27 °C; under 
these conditions the total conversion of the substrate was detected after 5 h with the formation of (S)-
2 i in 72 % ee. At higher substrate concentrations (150 mM) the same enantioselectivity was observed 
and a recovered yield of 73 % was obtained, which shows the possibility to apply these 
biotransformations on a preparative scale.  
HALOTOLERANCE SCREENING 
In this second part, a heterogeneous group of marine yeasts was studied from a physiological point 
of view in order to identify possible biocatalysts with enhanced performance.  
PRIMARY SCREENING 
Having the possibility to work on a second heterogeneous group of marine yeasts29, the ability to 
growth at different NaCl concentrations was tested on 18 strains with different genera/species, plus 
three of previous strains with interesting biocatalytic application (table 2.5). The screened strains 
belong to UBO Culture Collection of marine microorganisms isolated from different basins and, 
consequently, they are physiologically interesting for the identification of potential candidates to 
implement a biocatalytic strategy in sea water. The first screening was developed in YNB (yeast 
nitrogen base medium) plates at various NaCl concentrations, buffered at pH 6, with glucose as the 
only carbon source. In this way, the growth of microorganisms was mainly influenced by the presence 
of NaCl and monitored day by day by observing colonies formation (table 2.5; figure 2.2). 
 24h 48h 120h 
 
Strain 
% NaCl % NaCl8 % NaCl 
0 3 6 9 12 0 3 6 9 12 0 3 6 9 12 
(Mo 40) Debaryomyces 
hansenii 
** * * *  **** **** **** ***  **** **** **** **** **** 
(Mo 29) Cryptococcus sp ** *    **** **** ***   **** **** **** ***  
(Mo 35) Rhodotorula 
mucilaginosa 
** *    **** **** **** *  **** **** **** ****  
(Mo 38) Rhodosporidium 
diobovatum 
** *    **** **** ***   **** **** **** *** * 
(Mo 39) Candida marinus ** * *   **** **** *** *** * **** **** **** **** **** 
(Ex 7) Rhodotorula 
mucilaginosa 
** *    **** **** *** *  **** **** **** ****  
Ex 15 (Pichia 
guilliermondii) 
*** ** *   **** **** **** **  **** **** **** **** **** 
(Bio 1) Candida 
viswanathii 
*** **    **** **** **** **  **** **** **** **** ** 
(Bio2) Debaryomyces 
hansenii 
** * ** *  **** **** **** ** * **** **** **** **** **** 
(LM 16) Rhodotorula 
mucilaginosa 
** *    **** **** *** *  **** **** **** ****  
(LM18) Rhodotorula 
mucilaginosa 
** *    **** **** ** *  **** **** **** ****  
(LM 2) Meyerozyma 
guillermondi 
*** *** ** *  **** **** **** **  **** **** **** **** **** 
(Mo 36) Leucosporidium 
scottii 
*     *** *** *   **** **** **** ***  
(Mo 34) Hortaea 
werneckii 
     * * *   *** **** **** *** ** 
(Mo 31) Candida 
atlantica 
* *    **** **** **** **  **** **** **** **** **** 
(Mo 30) Phaeotheca 
triangularis 
           * ** **  
(Mo22) Sporobolomyces 
roseus 
     ** **    **** **** ***   
(LM 9) Meyerozyma 
guillermondi 
*** ** *   **** **** **** **  **** **** **** **** ** 
Table 2.5. Primary screening, colony growth (*) at different NaCl concentrations at 24.48 and 120 hours. The * is a 
qualitative indication of growth based on dilution spots. 
 
Figure 2.2. Plate growing was analysed at different concentrations of NaCl: 0%, 3%, 6%, 9%, 12% and at various 
times. The picture shows some examples. 
As result of the first screening, 10 microorganisms (table 2.6) were selected for a deeper investigation 
under saline stress.  
ID                      Strain 
 
O.D. (optical density) Limiting [NaCl] 
Bio 2 Debaryomyces hansenii 47 12% (A) 
Mo 31 Candida atlantica 33 9% (B) 
Mo 38 Rhodosporidium diobovatum 29 9% (B) 
Mo 39 Candida marinus 48 12% (A) 
Mo 40 Debaryomyces hansenii 36 12% (A) 
Mo 34 Hortaea  werneckii 19 9% (B) 
 Table 2.6. 48 h O.D. and limiting conditions: (A) for 12% NaCl and (B) for 9% NaCl. 
 
 
SECONDARY SCREENING 
The subsequent screening was set up in liquid medium with 4% sea salts that mimic the marine 
mineral composition and with a limited concentration of NaCl. The selected strains were inoculated 
at initial concentration of 0.1 O.D. and the growth was followed for 96 hours. O.D. values were 
recorded every two hours at 600 nm. 
 
Figure 2.3. A standard yeast growth curve. The y axis represents the optical density at 600nm in logarithmic 
scale, while on the x axis there is time (h) of readings. The μmax corresponds to the slope of the line in the linear 
exponential phase. 
Secondary screening shows the presence of halotolerant strains. Based on the previous data, no strain 
has a μmax greater in the limit condition than the control. µmax is also higher in the medium with 4% 
sea salts than with 9% or 12% NaCl. This phenomenon is shown for all strains with the exception of 
Debaryomyces hansenii (UBOCC-A-208002) and Candida atlantica (UBOCC-A-208026). For these 
two microorganisms, the growth rate in 12% NaCl was higher than with 4% sea salts. The candidate 
strains for this work were chosen based on the results of the growth kinetics: Debaryomyces hansenii 
LM 2 Meyerozyma  guillermondi 30 12% (A) 
LM 9 Meyerozyma  guillermondi 31 9% (B) 
LM 16 Rhodotorula mucilaginosa 28 9% (B) 
LM 18 Rhodotorula mucilaginosa 26 9% (B) 
(UBOCC-A-208002), Candida atlantica (UBOCC-A-208026), Rhodosporidium diobovatum 
(UBOCC-A-208033), Hortaea werneckii (UBOCC -A-208029) and Phaeotheca triangularis 
(UBOCC-A-208025). 
 
Figure 2.4. 12% NaCl as limiting condition: comparison of μmax of control, 4% sea salts, 12% NaCl conditions. 
 
Figure 2.5. 9% NaCl as limiting condition: comparison of μmax of control, 4% sea salt, 9% NaCl conditions. 
 
Debaryomyces hansenii  
The strain Debaryomyces hansenii (UBOCC-A-208002), reported as Bio2 in figure 2.4, is one of the 
candidates selected in terms of μmax and final biomass at high concentrations of NaCl. Liquid cultures 
were set up in YNB and YPD under different conditions: control (no NaCl), with the addition of 4% 
sea salts and with12% NaCl. The growth in flasks under stirring at 28 °C was monitored for 48 hours. 
     
Figure 2.6. Growth curves in YNB and YPD in three different conditions: no NaCl (control); with the addition of 
4% sea salts (4% ss) and with 12% NaCl. On the x axis there is the time (h) while on y axis the optical density at 
600nm expressed in semi-logarithmic scale is reported.  
Observing the curves in figure 2.6, there is a manifest difference between the two media in terms of 
growth rate (μmax), saline stress response and final biomass. The choice of employing two media, one 
minimal and the other one rich in nutrient elements was aimed at understanding the optimal condition 
for salt stress response. A greater difference was observed in limit condition, which in the case of 
Debaryomyces hansenii (UBOCC-A-208002) is represented by the culture medium (YNB / YPD) 
with the addition of 12% NaCl. The strain shows a faster adaptation response in rich medium resulting 
in a shorter latency phase in comparison with the same condition in YNB. On the contrary, for the 
control condition and with 4% of sea salt, for both YNB and YPD, the lag phase is absent. Moreover, 
the difference between μmax of the control and μmax of 4% sea salts is minimal and the growth curves 
are almost overlapped. This would suggest that both the control condition and 4% sea salts condition 
do not create any adjustments due to stress adaptation for the strain tested.  
 
MATERIALS AND METHODS 
MATERIALS 
All reagents and solvents were obtained from Sigma–Aldrich-Fluka and used without further 
purification or drying. TLC was performed with Merck silica gel 60 F254 pre-coated plates. Silica 
gel column chromatography was performed on silica gel 60 (40–63 mm particle size). Substrate 1h 
was kindly gifted by Dr. Roberto Lenna (Industriale Chimica, Italy); substrate 1i (2-acetylamino-6-
oxo-4,5,6,7- tetrahydrobenzothiazole) was prepared following a procedure described previously27. 
For each compound, the alcohol racemic mixture was obtained by NaBH4 reduction (0.25 mm of 
substrate). Natural seawater (pH 7.5) was collected from the Camogli beach (Genova, Italy) and 
maintained at 4 °C after microfiltration; a water salinity of 35 PSU was reported by ARPA (Agenzia 
Regionale Prevenzione e Ambiente) for this area.  
CHARACTERISATION  
1H and 13C NMR spectra were recorded by using a Nuclear magnetic resonance (NMR) spectra at 
300 K on a Bruker-Avance 500 MHz spectrometer operating at 500.13 and 125.76 MHz for 1H and 
13C acquisitions, respectively. Chemical shifts (δ) of the 1H NMR and 13C NMR spectra are reported 
in ppm using the signal for residual solvent proton resonance as the internal standard (1H NMR: 
CDCl3 7.26, DMSO-d6 2.49, CD3OD 3.31 ppm; 
13C NMR: CDCl3 77.0 (central line), DMSO-d6 39.50 
(central line), CD3OD 49.00 (central line) ppm). HPLC analyses were performed by using a Jasco 
Pu-980 equipped with a UV/Vis detector Jasco UV-975. Chiral HPLC columns used: Chiralcel OD 
(4.6x250 mm, 5 mm Daicel), Chiralcel OJ-H (4.6x250 mm, 5 mm, Daicel), Chiralcel OD-H (4.6x250 
mm, 5 mm, Daicel), Chiralpak IA (4.6x250 mm, 5 mm, Daicel), Lux cellulose-2 column (4.6x250 
mm, 5 mm, Phenomenex) and Lux cellulose 3 column (4.6x250 mm, 5 mm, Phenomenex). Optical 
rotatory power determinations were performed by a Perkin–Elmer (mod. 241) polarimeter in a 1 dm 
cell at 20 °C, setting the wavelength at 589 nm or at 546 nm. Elemental analyses were performed by 
using a Carlo Erba Model 1106 Elemental Analyzer for C, H and N, and the obtained results were 
within 0.4% of the theoretical values.  
MICROORGANISMS 
All isolated microorganisms are available in the UBO Culture Collection (http://www.univ-
brest.fr/ubocc). 
ID strain Phylum UBOCC number Depth 
LM 1 Meyerozyma guillermondi Ascomycota UBOCC-A-214022 37,1 mbsf 
LM 2 Meyerozyma guillermondi Ascomycota UBOCC-A-214008 137,13 mbsf 
LM 3 Meyerozyma guillermondi Ascomycota UBOCC-A-214007 24,6 mbsf 
LM 4 Rhodotorula mucilaginosa Basidiomycota UBOCC-A-214045 137,13 mbsf 
LM 5 Meyerozyma guillermondi Ascomycota UBOCC-A-214013 24,6 mbsf 
LM 6 Meyerozyma guillermondi Ascomycota UBOCC-A-214014 24,6 mbsf 
LM 7 not sequenced  UBOCC-A-214004 3,76 mbsf 
LM 8 Rhodotorula mucilaginosa Basidiomycota UBOCC-A-214143 24,6 mbsf 
LM 9 Meyerozyma guillermondi Ascomycota UBOCC-A-214015 21,1 mbsf 
LM 10 Rhodotorula mucilaginosa Basidiomycota UBOCC-A-214039 24,6 mbsf 
LM 13 Rhodotorula mucilaginosa Basidiomycota UBOCC-A-214049 21,1 mbsf 
LM 14 Rhodotorula mucilaginosa Basidiomycota UBOCC-A-214040 34,1 mbsf 
LM 15 Rhodotorula mucilaginosa Basidiomycota UBOCC-A-214034 37,1 mbsf 
LM 16 Rhodotorula mucilaginosa Basidiomycota UBOCC-A-214025 3,76 mbsf 
LM 17 Rhodotorula mucilaginosa Basidiomycota UBOCC-A-214046 345,5 mbsf 
LM 18 Rhodotorula mucilaginosa Basidiomycota UBOCC-A-214036 765 mbsf 
LM 19 Rhodotorula mucilaginosa Basidiomycota UBOCC-A-214051 37,1 mbsf 
LM 20 Rhodotorula mucilaginosa Basidiomycota UBOCC-A-214043 34,1 mbsf 
LM 21 Rhodotorula mucilaginosa Basidiomycota UBOCC-A-214006 3,76 mbsf 
LM 22 Rhodotorula mucilaginosa Basidiomycota UBOCC-A-214026 34,1 mbsf 
Bio1 Candida viswanathii Ascomycota UBOCC-A-208001 2620 mbsl 
Bio2 Debaryomyces hansenii Ascomycota UBOCC-A-208002 2620 mbsl 
Ex15 Pichia guilliermondii Ascomycota UBOCC-A-208004 700 mbsl 
Ex7 Rhodotorula mucilaginosa Basidiomycota UBOCC-A-208010 2300 mbsl 
Mo22 Sporobolomyces roseus Basidiomycota UBOCC-A-208018 2300 mbsl 
Mo29 Cryptococcus sp. Basidiomycota UBOCC-A-208024 2300 mbsl 
Mo30 Phaeotheca triangularis Ascomycota UBOCC-A-208025 2300 mbsl 
Mo31 Candida atlantica Ascomycota UBOCC-A-208026 2300 mbsl 
Mo34 Hortaea werneckii Ascomycota UBOCC-A-208029 2300 mbsl 
Mo35 Rhodotorula mucilaginosa Basidiomycota UBOCC-A-208030 2300 mbsl 
Mo36 Leucosporidium scottii Basidiomycota UBOCC-A-208031 2300 mbsl 
Mo38 Rhodosporidium diobovatum Basidiomycota UBOCC-A-208033 2300 mbsl 
Mo39 Candida marinus Ascomycota UBOCC-A-208034 2300 mbsl 
Mo40 Debaryomyces hansenii Ascomycota UBOCC-A-208035 2300 mbsl 
Table 2.7. Marine yeasts employed and and sampling depths: mbsf = meter below seafloor; mbsl = meter below 
sea level. 
The first group presents 8 strains of Meyerozyma guilliermondii and 12 strains of Rhodotorula 
mucilaginosa isolated previously2 from different deep-sub-seafloor sediment depths (mbsf= meter 
below the seafloor) at Canterbury Basin (New Zealand 44°56 26.62"S, 172°1 36.30"E).   
 
The second group, on the other hand, derives from a second collection of marine microorganisms of 
different origins: South Pacific West (Lau Basin), Mid-Atlantic Ridge (Rainbow), Mid-Atlantic 
Ridge (Lost City). These strains were isolated from marine fauna present in "hydrothermal vents" 
(table 2.8). 
 
Table 2.8. Collection of marine yeasts associated with fauna in the hydrothermal vents1. 
 GROWING MEDIUM 
YNB (YEAST NITROGEN BASE) MEDIUM 
It is a defined mineral medium containing specific concentrations of mineral salts, vitamins and other 
elements (traces). As nitrogen source, ammonium sulphate can be added.  
 
 
 
 
 
 
 
 
YPD MEDIUM 
 It is a rich medium in term of carbon and 
nitrogen sources. 
 
 
 
HALOTOLERANCE SCREENING 
SCREENING ON PLATE 
Plate screening was set up for 18 yeast strains and allowed a first analysis of strain growth and strain 
patterns at different NaCl concentrations. For this preliminary analysis YNB plates were prepared at 
all different concentrations of NaCl and growth was evaluated up to 120 hours. 
From glycerol stocks, the yeasts were re-activated on YPD Solid Broth and grown to 28 °C for 48 
hours. They were then pre-inoculated in buffered YNB in Erlenmeyer flasks, allowed to grow at 28 
°C, 150 rpm for 48 hours. Growth was evaluated by reading optical density (O.D.) at 600 nm. Each 
strain was deposited on plate in four dilutions: 105, 104, 103, 102 cell number (figure 2.2). The protocol 
was repeated for all the four conditions of increasing salinity: 0% NaCl, 3% NaCl, 6% NaCl, 9% 
NaCl, 12% NaCl. 
COMPOSITION CONCENTRATION 
YNB (BD-Difco) 1.7 g/L 
MES buffer 1 M 
Glucose 20 g/L 
(NH4)2SO4 5 g/L 
COMPOSITION CONCENTRATION 
Yeast extract 10 g/L 
Tryptone 20 g/L 
Glucose 20 g/L 
SCREENING IN LIQUID AND GROWTH KINETICS 
A liquid screening was then performed on the 10 strains with the most interesting results in terms of 
tolerance at high NaCl concentrations. Growth kinetics analysis was performed in microtiter (96-
wells of multiwell plate) and for each strain three different conditions were analysed: 
 YNB + 0% NaCl (control) 
 YNB + 4% sea salts (sea water control) 
 YNB + 9% (limit condition) 
 YNB + 12% NaCl (limit condition) 
For each strain, each condition was in duplicate. 
The selected strains were pre-inoculated) in buffered YNB Erlenmeyer flasks. Growth was monitored 
by reading the O.D. at 600 nm after 48 hours (table 2.6). After the inoculum at O.D. of 0.1 (about 1 
x 106 cells/mL) the growth was followed for about 96 hours.  
 
Scheme 2.9. Design of the first liquid screening in 96 multiwell plate (B stands for blank). 
 
Gene 5 microplate reader (Biotek) was set to record the optical density of the culture every two hours; 
although static, the cell suspension was mixed by rapid agitation before each reading. Once all the 
values for each strain and each conditions, the growth curves were designed and for each one the rate 
and duplication time were calculated. 
FLASK CELL GROWTH 
The growth of the most promising strains in term of halotolerance was followed also in flask 
employing a Pharmacia®Biotech Ultrospec 1000 spectrophotometer. Based on the results obtained 
from these screenings, the best candidates in terms of halotolerance were selected for a deeper 
physiological characterization and investigated from biocatalytic point of view. 
 
BIOTRANSFORMATIONS 
The screening of growth was performed in Erlenmeyer flasks (100 mL) that contained 10 mL of YPD 
liquid prepared with freshwater or natural seawater30 and incubated in an orbital shaker at 180 rpm at 
28 °C for 48 h. Samples were withdrawn at appropriate intervals and used to monitor the cell growth 
by measuring the O.D. at 600 nm by using a spectrophotometer after appropriate dilution. For dry 
weight determination, washed culture samples were filtered through a 0.45 μm glass microfiber GF/A 
filter (Whatman) and dried for 24 h at 110 °C. The results were an average of five replicates. 
Reductions of all substrates were performed with freshly prepared cells, grown in freshwater-YPD or 
in YPD-seawater. Cells grown in freshwater-YPD medium (50 mg dry weight/mL) were suspended in 
phosphate buffer (pH 7.5, 0.1m), whereas cells grown in seawater-YPD medium (50 mg dry weight/mL) 
were suspended in natural microfiltered seawater. The biotransformations of 1a–g were performed in 
the presence of 5% glucose by adding the substrates as concentrated solution in DMSO (final 
concentration of co-solvent 1%). The biotransformations of ethyl secodione derivative 1h was 
performed using freshly cells suspended in seawater in the presence of 3.5% EtOH both to increase 
the solubility and to favour cofactor regeneration. The biotransformations of 1i were performed using 
fresh cells suspended in seawater in the presence of different co-solvents.  
The biotransformations were performed on a 25 mL scale and kept under reciprocal shaking (150 
rpm) at the desired temperature. Once the reaction was over, EtOAc (12 mL) was added, and the 
resulting mixture was shaken and centrifuged; the aqueous phase was extracted twice more with 12 
mL of EtOAc. The organic phases were collected and dried over Na2SO4 and the solvent was 
evaporated. The crude residues were purified by flash chromatography. 
ARYL METHYLKETONI 
Cells were grown in freshwater-YPD or in seawater-YPD medium. Biotransformations were 
performed for 24 h with freshly prepared cells (50 mg dry weight mL−1). Cells grown in freshwater-YPD 
medium were suspended in phosphate buffer (pH 7.5, 0.1 M), whereas cells grown in seawater-YPD 
medium were suspended in seawater. Biotransformations were performed in the presence of 5 % 
glucose. 
β – KETONITRILES 
Biotransformations were performed for 24 h with freshly prepared cells (50 mg dry weight mL−1) 
suspended in seawater in the presence of 5 % glucose. Yields and enantioselectivity after 24 h. 
ETHYL SECODIONE DERIVATIVE 
Biotransformations were performed for 24 h with freshly prepared cells (50 mg dry weight mL−1) 
suspended in seawater in the presence of 3.5 % EtOH. Yields and diastereoselectivity after 24 h. 
PRAMIPEXOLE KETO INTERMEDIATE 
Biotransformations were performed for 24 h with freshly prepared cells (50 mg dry weight mL−1) 
suspended in seawater (pH 5.6) in the presence of 5 % glucose. Yields and enantioselectivity were 
determined after 24 h. In this case, seawater was used at pH 5.6 because of the low stability of the 
substrate at a higher pH.  
 
PURIFICATION AND CHEMICAL CHARACTERISATION 
 
(S)-1-Phenylethanol (2 a) 
The reaction progress and ee were determined by using HPLC using a Chiralcel OD column (n-
hexane/iPrOH 95:5, 0.7 mL min−1, 254 nm): tr (R)-2 a 14.2 min, tr (S)-2 a 18.0 min.31 Oil. Rf=0.4 
(hexane/EtOAC=8:2); [α]  =−40.0 (c=0.5 chloroform) lit32. [α]  =−39.2 (c=2.54 chloroform); 1H 
NMR (300 MHz, CDCl3): δ=7.20–7.35 (m, 5 H), 4.85 (q, J=6.4 Hz, 1 H), 1.46 ppm (d, J=6.4 Hz, 
3 H); 13C NMR (75 MHz, CDCl3): δ=145.9, 128.5, 127.5, 125.4, 70.4, 25.2 ppm; elemental analysis 
calcd (%) for C8H10O (122.07): C 78.65, H 8.25; found: C 78.38, H 8.01. 
(S)-1-Pyridin-3yl-ethanol (2 b) 
The reaction progress and ee were determined by using HPLC using a Phenomenex Lux cellulose 2 
column (n-hexane/iPrOH 90:10, 0.7 mL min−1, 254 nm): tr (R)-2 b 20.46 min, tr (S)-2 b 25.30 min.33 
Oil. Rf=0.3 (EtOAc); [α]  =−38.04 (c=0.4 ethanol) lit34. =−39.0 (c=0.93 ethanol); 1H NMR (300 
MHz, CDCl3): δ=8.46–8.33 (m, 2 H), 7.75–7.70 (m, 1 H), 7.24 (dd, J=8.0, 5.0 Hz, 1 H), 4.90 (q, 
J=6.5 Hz, 1 H), 4.5 (br s, 1 H, OH), 1.49 ppm (d, J=6.5 Hz, 3 H); 13C NMR (75 MHz, CDCl3): 
δ=148.0, 147.0, 141.8, 133.5, 123.5, 67.5 25.1 ppm; elemental analysis calcd (%) for C7H9ON 
(123.07): C 68.27, H 7.37, N 11.37; found: C 68.55, H 7.67, N 11.10. 
(S)-(1-Thiophen-2-yl)ethanol (2 c) 
The reaction progress and ee were determined by using HPLC using a Phenomenex Lux cellulose–3 
column (n-hexane/iPrOH 90:10, 0.5 mL min−1, 254 nm): tr (S)-2 c 13.5 min, tr (R)-2 c 15.90 min35. 
Oil. Rf=0.3 (hexane/EtOAc=8:2); [α]  =−20.80 (c=0.2 chloroform) lit35. [α]  =−23.2 (c=0.79 
chloroform); 1H NMR (300 MHz, CDCl3): δ=7.25–7.18 (m, 1 H), 6.95–6.92 (m, 2 H), 5.07 (q, 
J=6.5 Hz, 1 H), 2.54 (br s, 1 H, OH), 1.56 ppm (d, J=6.5 Hz, 3 H); 13C NMR (75 MHz, CDCl3): 
δ=150.0, 126.6, 124.4, 123.2, 66.2, 25.2 ppm; elemental analysis calcd (%) for C6H8OS (128.03): C 
56.22, H 6.29; found: C 56.04, H 6.58. 
(S)-(1-Furan-2-yl)ethanol (2 d) 
The reaction progress and ee were determined by using HPLC using a Phenomenex Lux cellulose–3 
column (n-hexane/iPrOH 98:2, 0.5 mL min−1, 220 nm): tr (S)-2 d 19.3 min, tr (R)-2 d 21.3 min.35 
Oil. Rf=0.3 (hexane/EtOAc=8:2); [α]  =−20.5 (c=0.2 chloroform) lit34. [α]  =−13.6 (c=0.55 
chloroform); 1H NMR (400 MHz, CDCl3): δ=7.36 (dd, J=2.0, 1.0 Hz, 1 H), 6.32 (dd, J=3.0, 2.0 Hz, 
1 H), 6.22 (d, J=3.0 Hz, 1 H), 4.86 (q, J=6.5 Hz, 1 H), 2.35 (br s, 1 H, OH), 1.52 ppm (d, J=6.5 Hz, 
3 H); 13C NMR (100 MHz, CDCl3): δ=157.7, 141.8, 110.1, 105.1, 63.6, 21.2 ppm26; elemental 
analysis calcd (%) for C6H8O2 (112.05): C 64.27, H 7.19; found: C 63.97, H 7.34. 
(S)-3-Hydroxy-3-phenylpropanenitrile (2 e) 
The reaction progress and ee were determined by using HPLC using a Chiralcel OJ-H column (n-
hexane/iPrOH 90:10, 1.0 mL min−1, 220 nm), tr (S)-2 e 24.5, tr (R)-2 e 31.1 min.23Oil. Rf=0.4 
(hexane/EtOAc=7:3); [α]  =−58.5 (c=1.0, EtOH) lit.24 [α]  =−57.7 (c=2.6, EtOH)]; 1H NMR (300 
MHz,CDCl3): δ=2.74 (d, J=6.1 Hz, 2 H), 5.01 (t, J=6.1 Hz, 1 H), 7.36–7.39 ppm (m, 5 H); 13C 
NMR (75 MHz,CDCl3): δ=27.9, 70.0, 117.4, 125.5, 128.8, 128.9, 141.1 ppm; elemental analysis 
calcd (%) for C9H9ON (147.07): C 73.45, H 6.16, N 9.52; found: C 73.01, H 6.31, 9.32. 
(S)-3-(2-Thienyl)-3-hydroxypropanenitrile (2 f) 
The reaction progress and ee were determined by using HPLC using a Chiralcel OJ-H column (n-
hexane/iPrOH=90:10, 1.0 mL min−1, 220 nm), tr (S)-2 f 27.0, tr (R)-2 f 32.3 min.23 Oil. Rf=0.3 
(hexane/EtOAc=7:3); [α]  =−19.4 (c=1.0, CHCl3) lit.34 [α]  =−16.71 (c=1.01, CHCl3); 1H NMR 
(300 MHz,CDCl3): δ=2.85 (d, J=6.2 Hz, 2H), 3.04 (s, br, OH), 5.26 (t, J=6.2 Hz, 1 H), 6.98–7.00 
(m, 2 H), 7.06–7.07 (d, J=3.5 Hz, 1 H), 7.29–7.32 ppm (m, 1 H); 13C NMR (75 MHz, CDCl3): 
δ=28.2, 66.2, 117.1, 124.7, 125.7, 127.1, 144.5 ppm; elemental analysis calcd (%) for C7H7ONS 
(153.02): C 54.88, H 4.61, N 9.14; found: C 54.81, H 4.81, 8.92. 
(S)-3-(2-Furyl)-3-hydroxypropanenitrile (2 g) 
The ee was determined by using HPLC using a Chiralcel OJ-H column (n-hexane/iPrOH=90:10, 1.0 
mL min−1, 220 nm), tr (S)-2 g 21.9, tr (R)-2 g 25.6 min.23 Oil. Rf=0.3 (hexane/EtOAc=7:3); [α] 
=−40.2 (c=1.0, EtOH) lit.24 [α]  =−38.6 (c=1.3, CHCl3); 1H NMR (300 MHz,CDCl3): δ=2.57 (s, br, 
OH), 2.88 (d, J=6.2 Hz, 2 H), 5.05 (t, J=6.2 Hz, 1 H), 6.37–6.41 (m, 2 H), 7.41–7.42 ppm (m, 1 H); 
13C NMR (75 MHz,CDCl3): δ=24.9, 63.8, 107.5, 110.6, 116.9, 142.9, 152.8 ppm; elemental 
analysis calcd (%) for C7H7O2N (137.05): C 61.31, H 5.14, N 10.21; found: C 61.06, H 5.36, 9.94. 
1 -Benzoylbutanenitrile (3 e) 
Oil. Rf=0.4 (hexane/EtOAc=7:3). 
1H NMR (300 MHz, CDCl3): δ=1.16 (t, J=7.7 Hz, 3 H), 2.02–2.15 
(m, 2 H), 4.30 (dd, J=6.2, 4.3 Hz, 1), 7.49–7.56 (m, 2 H), 7.65 (d, J=7.6 Hz, 1 H), 7.95 ppm (d, 
J=6.7 Hz, 2 H); 13C NMR (75 MHz, CDCl3): δ=11.89, 23.77, 41.38, 128.68, 128.92, 129.31, 
130.38, 133.93, 134.63, 170.91, 190.88 ppm; elemental analysis calcd (%) forC11H11ON (173.08): 
C 76.28, H 6.40, N 8.09; found: C 75.92, H 6.50, 7.97. 
(13S,17S)-E-13-Ethyl-3-methoxy-8,14-secogona-1,3,5(10),9(11)-tetraene-17-
ol-14-one (2 h) 
The reaction progress, ee and diastereomeric excess (de) were determined by HPLC using a Lux 
Cellulose-2 column (n-hexane/iPrOH 85:15; 0.5 mL min−1 254 nm); tr (13S, 17S)-2 h 18.87 min, 
(13S, 17R)-2 h 20.62 min, (13R, 17S)-2 h 23.34 min, (13R, 17S)-2 h, 24.61 min.27White solid. 
Rf=0.3 (hexane/EtOAc=1:1). ee=84 %. 1H NMR (300 MHz,C3D6O): δ=0.82 (t, J=7.5 Hz, 3 H), 1.53 
(non, J=7.5 Hz, 2 H), 1.78 (qui, J=6.2 Hz, 2 H), 1.95–2.07 (m, 1 H), 2.23–2.31 (m, 3 H;), 2.43–2.46 
(m, 2 H; CH2), 2.51 (t, J=6.2 Hz, 2 H), 2.74 (t, J=6.2 Hz, 2 H), 3.77 (s, 3 H), 4.13 (d, J=4.2 Hz, 1 H; 
OH), 4.32 (q, J=5.3 Hz, 1 H), 6.0 (t, J=7.5 Hz, 1 H), 6.64 (d, J=2.8 Hz, 1 H), 6.72 (dd, J=2.8, 8.7 
Hz, 1 H), 7.50 ppm (d, J=8.7 Hz, 1 H); 13C NMR (300 MHz,C3D6O): δ=8.2, 23.6, 25.3, 26.6, 26.8, 
28.4, 30.9, 34.8, 54.9, 57.2, 75.1, 112.8, 113.2, 118.1, 125.3, 129.6, 135.4, 138.7, 159.0, 219.1 ppm; 
elemental analysis calcd (%) for C20H26O3 (314.19): C 76.40, H 8.33; found: C 76.11, H 8.39. 
(S)-2-Acetylamino-6-hydroxy-4,5,6,7-tetrahydrobenzothiazole (2 i) 
The reaction progress and ee were determined by using HPLC using a Chiralpak IA column (n-
hexane/iPrOH 8:2 as eluent, flow rate: 0.7 mL min−1, 254 nm), tr (R)-2 i 10.9 min, tr (S)-2 i 14.8 
min27. Yellowish solid. Rf=0.25 (CH2Cl2/MeOH, 95:5). ee=64 %. 1H NMR (300 MHz,CD3OD): 
δ=1.91 (dddd, J=14.2, 8.6, 7.7, 5.9 Hz, 1 H), 2.04 (dddd, J=14.2, 6.2, 5.9, 2.9 Hz, 1 H), 2.26 (s, 
CH3, 3 H), 2.61–2.71 (m, 2 h), 2.79 (dddd, J=16.5, 5.9, 5.9, 1.8 Hz, 1 H), 2.99 (ddd, J=15.7, 4.7, 1.8 
Hz, 1 H), 4.15 ppm (dddd, J=8.6, 6.9, 4.7, 2.9 Hz, 1 H); 13C NMR (300 MHz, CD3OD): δ=21.2, 
23.2, 30.5, 30.7, 66.2, 120.9, 143.2, 156.4, 169.1 ppm; elemental analysis calcd (%) for 
C9H12O2N2S (212.06): C 50.92, H 5.70, N 13.20; found: C 50.96, H 5.89 N 12.85. 
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WHOLE CELL SCREENING – MARINE BACTERIA 
 
  
In this section the focus will be on biocatalytic potential of varied range of bacterial strains collected 
from one of the most peculiar marine habitats. Keto-reductase and transaminase enzymatic activities 
were investigated with whole cells in order to identify a possible gene target to express as recombinant 
enzyme with enhanced performances. 
BACKGROUND  
MARINE BACTERIA 
In the context of this doctoral thesis, the enzymatic activities of 33 marine strains from four different 
deep hypersaline anoxic basins (DHABs) located in the eastern area of the Mediterranean Sea have 
been studied. This project was involved in the European research project BIODEEP1 
(Biotechnologies from the Deep), which aimed to explore unique marine habitats in order to isolate 
and cultivate marine microorganisms, offering new opportunities for the study of new significant 
enzymatic activities. The bacteria collected from DHABs have adapted to high salinity, anoxia and 
high pressures that may have affected the expression of unique cellular features of interest in many 
industrial applications.  
The DHABs are located in an area of the Mediterranean called Mediterranean Ridge (figure 3.1); it 
is the result of the convergence between the African, European and Aegean platforms. The 
hypersaline basins are probably the result of the melting of underground deposits (3200-3600m of 
depth) of salt (Messinians evaporites) that were exposed to seawater because of tectonic activities 
during Miocene period (from 26 million to 2.5 million years ago). The brine in DHABs is 
characterized by anoxia conditions, high pressure (≈35 MPa), saturated salts concentrations2–5, high 
concentrations of MgCl2 (≈5 M) and no light that make them some of the most extreme habitats on 
earth5,6. 
 
 
 
 
 
Figure 3.1. Localisation of deep hypersaline anoxic basins in Mediterranean Sea. The L’Atalante, Urania and 
Discovery are located in a and Bannock in b. 
The brine high density limits the mixing with the overlying oxygen-rich waters, creating a chemocline 
of 1-3 m of the thickness. It is clear from previous studies that every DHABs have distinct 
geochemical characteristics from the other ones2,4,7. The L’Atalante, Bannock and Urania brine has a 
similar ionic composition, but the salinity of Urania is lower in contrast to the concentration of 
methane and sulphate which is, however, considerably higher than the other two. The main difference 
with the Discovery basin lies in its high concentration of Mg2+ions (about 5M) and a lower 
concentration of Na+ions.  
 
Table 3.1. Element composition of deep hypersaline anoxic basins and sea water6. 
Physical separation due to different water density and thousands of year of evolutionary pathway 
have probably made possible the development of specific and diverse microbial communities in the 
four different basins. In the past, these high cation concentrations convinced the researchers that this 
condition was incompatible with life8,9, but recently the presence of metabolically active microbial 
communities has been demonstrated6. Through the combined study of 16S rRNA and enzymatic tests, 
in all four basins, an active reduction of methane, sulfate and an important heterotrophic and 
chemoautotrophic activities has been demonstrated. Instead, the waters above them show a different 
structure of the microbial community10. Microbial communities prevailing in the Discovery basin 
belong to the Bacteria kingdom and same happens for L’Atalante and Bannock basins, while in 
Urania basin there is a prevalent prevalence of the Archaea microorganisms. 
In all four hypersaline anoxic basins, a microbial population belonging to Bacteria kingdom is highly 
diversified compared to the Archaea one; a biodiversity that was not found in the Urania basin. After 
a more specific analysis of 16S rRNA gene sequences, it has also emerged that hypersaline anoxic 
basins are populated by high percentages of microbial species belonging to γ-, δ-, and ε-
proteobacteria, sphingobacteria and halobacteria. This isolation may have resulted in the evolution of 
specific microbial communities in each DHAB. In fact, through biodiversity analysis of the seawater 
interface, several taxonomic categories have been identified, including new phylogenetic groups, 
organized in colonies and heavily stratified in the “deep-water ecosystem”11–16. 
MARINE BACTERIA BIOCATALYSIS 
As fairly described by De Vitis et al.17 these peculiar microorganisms isolated from DHABs on the 
Mediterranean Ridge have already showed interesting biocatalytic features applied in a kinetic 
resolution of the propyl ester of anti-2-oxotricyclo[2.2.1.0]heptan-7-carboxylic acid, a key 
intermediate for the prostaglandin D-cloprostenol18 (scheme 3.1).  
 
Scheme 3.1. Kinetic resolution of anti-2-oxotricyclo[2.2.1.0]heptan-7-carboxylic acid by newly isolated marine 
bacteria17. 
 
The 33 strains were screened on racemic (R,S)-1 and some of them have showed enantioselective 
keto-reductase and esterase activity. Virgibacillus pantotheticus 21D showed high halotolerance, 
enantioselective keto-reductase activity in the presence of glucose, and esterase activity was prevalent 
in the absence of glucose. 
 
 
 
Table 3.2. Activity on racemic propyl ester 1 of whole cells of marine bacteria. a Biotransformation in the 
presence of glucose (5%); b Biotransformation in the absence of glucose. 
 
In both cases, enantiomerically pure unreacted substrate could be easily recovered and purified at 
molar conversion below 57–58 %.  
 
ω-TRANSAMINASE 
As it was reported in the introduction of this PhD thesis, ω-transaminases (ω-TAs), also called 
aminotransferases, are enzymes that transfers an amino group from an amino-donor into a carbonyl 
moiety of an amino-acceptor, whereby at least one of the two substances is not an α-amino acid or an 
a-keto acid. ω-TAs offer a unique opportunity for the asymmetric synthesis or kinetic resolution 
(scheme 3.2) of bioactive compounds that possess a chiral amine moiety, starting from prochiral 
ketones or low-cost racemic amines19. 
 
 
 
Scheme 3.2. Kinetic resolution starting with racemic amines is 
limited by 50% maximum yield. Theoretically, a 100% yield is 
possible in asymmetric synthesis from prochiral ketones if the 
equilibrium can be shifted appropriately19. 
 
 
 
This enzymatic catalysis consists of two steps:  
 deamination of an amino acid or amine (amino-donor) releasing amino-donor product; 
 amination of a keto acid, ketone or aldehyde (amino-acceptor) producing a new amino acid 
or amine. 
All aminotransferases (EC 2.6.1.X) reported to date require the same coenzyme, namely pyridoxal-
5’-phosphate (PLP), which serves as a molecular shuttle for ammonia and electrons between the 
amino donor and the amino acceptor (scheme 3.3). During the reaction, PLP is reversibly 
interconverted to pyridoxamine (PMP). In the catalytic cycle, the amino donor binds first to the 
enzyme, PLP is aminated to PMP, and the respective keto product of the amino donor is released. 
The transamination is finalized by transferring the amino group from PMP to the acceptor molecule, 
thereby closing the catalytic cycle through the liberation of PLP. 
  
Scheme 3.3. Proposed reaction mechanism of an (S)‐selective ω‐transaminase20. PLP is, in the holo-enzyme, 
covalently bound to a lysine residue (top left) as an internal aldimine. An amino donor, here (S)‐1‐
phenylethylamine, reacts with the internal aldimine to form PMP and a keto compound (here acetophenone). 
Then, a keto substrate, here pyruvate, reacts with PMP to form alanine. This equilibrium reaction in this case 
strongly favours the products. Adapted from the mechanism deduced for aspartate α‐transaminase21,22. 
 
STEREOSELECTIVITY 
Another appealing property of TAs is their extraordinary stereoselectivity19.With the almost exclusive 
substrate-binding mode constrained by the relative position of PLP and two substrate-binding pockets 
of different sizes (figure 3.2), the enantiomeric excess of the chiral products is remarkably high. These 
distinguished natural properties have brought TAs to the attention of the biocatalysis community23–
25. 
 
 
 
 
Figure 3.2. PLP-dependent fold class I (S)-amine transaminase binding pocket: small (B) and large (A) binding 
pocket26. 
A more detailed description of ω-TAs is presented in the chapter about Virgibacillus pantothenticus 
ω-transaminase. 
PROJECT AIM 
Starting from the encouraging results achieved by marine bacteria keto-reductions, the idea was to 
exploit this ability on pramipexole keto-intermediate, as done with marine yeasts previously.  
 
On the other hand, the possibility to convert pramipexole ketone intermediate into the optically pure 
amine could be realised by a ω-transaminase enzyme (ω-TA) in a one-pot bioreaction instead of a 
multi-step synthetic pathway. Therefore, thirty-three marine bacteria species were screened to 
identify a transaminase activity. According to transaminase biocatalytic applications, where cofactor 
recycling is not needed, the aim in this case was to express and employ a recombinant enzyme. 
 
RESULTS AND DISCUSSION 
KETO-REDUCTASE 
The most promising strains belonging to BIODEEP collection were selected and screened on keto-
intermediate of pramipexole. The results showed a no particular enantioselectivity, with a general 
preference for (R)-enantiomer formation like Saccharomyces cerevisiae (table 3.3).  
 
STRAIN C (%) e.e.(%) SPECIFICITY 
11D 100 47 S 
15A 100 74 R 
3U 100 45 R 
3B 46,57 47 R 
5B tris 20 46 S 
6B 35,97 75 R 
7B 41,67 52 R 
26A 99 25 S 
9A 100 55 R 
12D 100 35 R 
21D 100 29 S 
Table 3.3. Bioconversion data with marine yeasts. 
 
ω-TRANSAMINASE 
The aim was to identify marine bacteria able to convert the keto-intermediate of pramipexole directly 
into the optically pure amine. Providing as amino acceptor the keto-intermediate and as amino donor 
methyl benzylamine the main activity seen was the keto-reductase one. For this reason, the 
subsequent approach was to try with model substrate27 (scheme 3.4). Hence, the thirty-three marine 
bacteria species were screened on a model substrates as pyruvate and racemic methyl benzylamine.  
 
Scheme 3.4. A transamination reaction where acetophenone and L-alanine is produced from rac‐1-
phenylethylamine and pyruvate, catalysed by an ω‐ transaminase (ω‐TA). 
The data showed here are a qualitative evaluation of presence of the product acetophenone after 6 h 
(due to volatile product) of bioconversion. All products from biotransformations were extracted in 
the same way and the samples injected in HPLC with the same dilution. This methodology was 
intentionally a rough screening because of whole cell metabolism that could hamper the conversion 
of pyruvate into L-alanine.  
STRAIN ACETOPHENONE STRAIN ACETOPHENONE STRAIN ACETOPHENONE 
11D - 3U ** 3B * 
15A - 9U - 5B tris - 
20D * 9B - 6B - 
15D - 13U ** 7B * 
17B * 18D - 5U - 
19B - 8B * 24U * 
11U bis 2 - 15B - 13A - 
12D * 13D - 14A - 
16U - 1U * 21D ** 
16U bis 2 - 2U * 26A - 
16A - 23U * 9A - 
Table 3. 4. Qualitative evaluation of acetophenone production by marine bacteria. * represents roughly the 
formation of trace of acetophenone. 
 
VIRGIBACILLUS PANTOTHENTICUS 
Based on the previous results17 in terms of halotolerance and keto-reductase activity, and on 
transaminase screening previously reported, the marine bacterium strain Virgibacillus pantothenticus 
21D was selected for the genome sequencing (next generation sequencing) in order to clone and 
express an ω-transaminase enzyme. 
 The strain 21D  isolated from seawater-brine interface of the deep hypersaline anoxic basin 
Discovery (35° 17′ N, 21° 41′ E), on the Mediterranean Ridge6. The isolate grows in presence of NaCl 
and MgCl2 at concentrations up to 9% and 9.52%, respectively, with optimum growth at 6-9% NaCl 
and 4.76% MgCl2; pH optimum (8-9) and temperature optimum (30-37°C) have been also 
determined.  
Genome sequencing data were deposited in The Seed database and genes were annotated by RAST 
software28. Automatic annotation of the genome showed that it contains genes that could help the 
bacterium to thrive osmotic stresses typically of extreme environments (osmotically activated L-
carnitine/choline ABC transporters, glycine betaine transporters, choline uptake and an ectoine 
synthase). The complete genome sequence of Virgibacillus pantothenticus 21D has been deposited 
in EMBL database (accession numbers: HG799644) and GenBank database (accession number: 
CP018622).  
Figure 3.3. The Seed representation of Rast Genome Annotations System of Virgibacillus pantothenticus 21D. 
MATERIALS AND METHODS 
MATERIALS 
All reagents and solvents were obtained from Sigma–Aldrich-Fluka and used without further 
purification or drying. TLC was performed with Merck silica gel 60 F254 pre-coated plates. Silica 
gel column chromatography was performed on silica gel 60 (40–63 mm particle size). Pramipexole 
keto intermediate (2-acetylamino-6-oxo-4,5,6,7- tetrahydrobenzothiazole) was prepared following a 
procedure previously described by Ferraboschi et al.29 
CHARACTERISATION  
1H and 13C NMR spectra were recorded by using a Nuclear magnetic resonance (NMR) spectra were 
recorded at 300 K on a Bruker-Avance 500 MHz spectrometer operating at 500.13 and 125.76 MHz 
for 1H and 13C acquisitions, respectively. Chemical shifts (δ) of the 1H NMR and 13C NMR spectra 
are reported in ppm using the signal for residual solvent proton resonance as the internal standard (1H 
NMR: CDCl3 7.26, DMSO-d6 2.49, CD3OD 3.31 ppm; 
13C NMR: CDCl3 77.0 (central line), DMSO-
d6 39.50 (central line), CD3OD 49.00 (central line) ppm). HPLC analyses were performed by using a 
Jasco Pu-980 equipped with a UV/Vis detector Jasco UV-975. Chiral HPLC columns used: Chiralpak 
IA (4.6x250 mm, 5 mm, Daicel), Chiralcell OD (4.6x250 mm, 5 mm, Daicel). Optical rotatory power 
determinations were performed by a Perkin–Elmer (mod. 241) polarimeter in a 1 dm cell at 20 °C, 
setting the wavelength at 589 nm or at 546 nm.   
MICROORGANISMS 
All microorganisms employed were isolated for BIODEEP project from four different deep 
hypersaline anoxic basins on Mediterranean Ridge. 
Table 3.5. List of all the marine bacterium strains employed in this research project with their identification 
number. 
 
MEDIA AND GROWING CONDITIONS 
CYSP (Casitone, Yeast extract, Soytone, Peptone) MEDIUM + 3% NaCl 
For both solid and liquid growing broth, the medium employed was CYSP18 medium + 3% NaCl to 
mimic the ionic strength of a marine environment. The growth in liquid was evaluated by measuring 
optical density (O.D.) at 600 nm with a single-ray Pharmacia®Biotech Ultrospec 1000 
spectrophotometer.  
COMPOSITION CONCENTRATION 
casitone 15 g/L 
yeast extract 5 g/L 
soitone 3 g/L 
peptone 2 g/L 
MgSO4*7H2O 15 mg/L 
FeCl3*6H2O 116 mg/L 
MnCl2*4H2O 20 mg/L 
NaCl 30 g/L (3%) 
 
 
BIOTRANSFORMATION 
Cells were grown in CYSP medium + 3% NaCl for 24h in an orbital shaker at 180 rpm at 28 °C for 
24 h. Biotransformations were performed suspending freshly prepared cells (50 mg dry weight mL−1) in 
10 mL of phosphate buffer (pH 7.5, 0.1 M) in Erlenmeyer flasks (100 mL). Bioconversions were kept 
at 28 °C at 180 rpm for 24h.Yields and enantioselectivity were checked during this time. 
For dry weight determination, washed culture samples were filtered through a 0.45 μm glass 
microfiber GF/A filter (Whatman) and dried for 24 h at 110 °C. The results were an average of five 
replicates.  
The biotransformation of pramipexole keto intermediate (5 mM) were performed by adding the 
substrate as concentrated solution in 2-propanol (final concentration of co-solvent 5%).  
The biotransformation of rac-1-phenylethylamine and sodium pyruvate were performed in the 
presence of 1% DMSO to increase the solubility and 50 g/L glucose. 
For extraction, EtOAc was added in each sample collected at various time for monitoring conversion 
and the resulting mixture was shaken and centrifuged; the organic phases were collected, dried under 
N2 and analysed by HPLC. 
 
PURIFICATION AND CHEMICAL CHARACTERISATION 
 2-Acetylamino-6-hydroxy-4,5,6,7-tetrahydrobenzothiazole 
The reaction progress and ee were determined by HPLC using a Chiralpak IA column (n-
hexane/iPrOH 8:2 as eluent, flow rate: 0.7 mL min−1, 254 nm), tr (R)-2 i 10.9 min, tr (S)-2 i 14.8 min.29 
Yellowish solid. Rf=0.25 (CH2Cl2/MeOH, 95:5). 
1H NMR (300 MHz,CD3OD): δ=1.91 (dddd, 
J=14.2, 8.6, 7.7, 5.9 Hz, 1 H), 2.04 (dddd, J=14.2, 6.2, 5.9, 2.9 Hz, 1 H), 2.26 (s, CH3, 3 H), 2.61–
2.71 (m, 2 h), 2.79 (dddd, J=16.5, 5.9, 5.9, 1.8 Hz, 1 H), 2.99 (ddd, J=15.7, 4.7, 1.8 Hz, 1 H), 4.15 
ppm (dddd, J=8.6, 6.9, 4.7, 2.9 Hz, 1 H); 13C NMR (300 MHz, CD3OD): δ=21.2, 23.2, 30.5, 30.7, 
66.2, 120.9, 143.2, 156.4, 169.1 ppm; elemental analysis calcd (%) for C9H12O2N2S (212.06): C 
50.92, H 5.70, N 13.20; found: C 50.96, H 5.89 N 12.85. 
Acetophenone  
The reaction progress and e.e. were determined by using HPLC using a Chiralcell OD column (n-
hexane/iPrOH 95:5 as eluent, flow rate: 0.7 mL min−1, 254 nm), tr 7.6 min. 
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RECOMBINANT ENZYMES 
 
  
Before checking the biocatalytic potential of marine recombinant enzyme, some commonly used 
enzymes were tested on pramipexole intermediates. 
BACKGROUND 
KETO-REDUCTASE 
This enzyme superfamily was already presented in previous chapters. Here, a focus on some strategies 
for cofactor regeneration are described. 
RECYCLING COFACTOR SYSTEM 
Most biocatalytic reactions involving reductions of ketones operated by DH require stoichiometric 
quantities of reducing equivalents which are provided in the form of NADH or NADPH. The high 
cost of these cofactors, however, strongly limits their use; for these reasons, in recent decades the 
interest in the development of in situ cofactor regeneration systems has increased considerably.  
 
Figure 4.1. Scheme of the reduction reaction of a carbonyl group by the substrate-coupled method (left) and the 
enzyme-coupled method (right). 
 
Enzymatic regeneration is a widely-diffused method, which involves two different methods of 
cofactor recycling: coupled enzyme method and coupled substrate method (figure 4.1). With the 
coupled enzyme method two distinct enzymes catalyze two different processes: the conversion of the 
main substrate and the cofactor recycling.  
Different classes of enzymes are used as auxiliary catalysts in recycling of cofactors: 
 Oxidation of formate to CO2 catalyzed by formate dehydrogenase (FDH). The main advantage 
of this reaction is that both the auxiliary substrate and the product are not harmless to the 
enzyme and easy to remove from the reaction environment. FHD is a commercial enzyme, 
stable and therefore easily immobilized, if protected by self-oxidation. 
 Glucose dehydrogenase (GDH) or glucose-6-phosphate dehydrogenase (G6PDH) are 
enzymes that oxidise glucose, allowing effective regeneration of both NADH and NADPH. 
The balance of this reaction is totally directed towards the formation of gluconolactone due 
to its spontaneous hydrolysis to gluconic acid. Active system, stable but very expensive. 
 Oxidation of alcohols with aldehyde dehydrogenase (ADH). The low cost of ADH and the 
volatility of ethanol and acetaldehyde make this method attractive for large-scale use. Due to 
low redox potential, only reactive carbonyl derivatives such as aldehydes or cyclic ketones 
can be reduced. With other substrates, the balance must be forced by using an excess  of 
ethanol or by removing the aldehyde. This latter result can be obtained by oxidizing the 
aldehyde to acetate with an aldehyde dehydrogenase, resulting in regeneration of a second 
low cofactor equivalent. 
 Direct reduction of NAD+ with hydrogenase; hydrogenases are bidirectional enzymes that 
catalyze the production and oxidation of molecular hydrogen. The regeneration of the 
NADPH directed by using this enzyme is probably the most elegant solution, as there is no 
by-product formation. 
An alternative method that does not require the implication of a second cofactor enzyme recirculation 
is referred to as a "substrate-coupled method" and is based on the addition of an auxiliary substrate 
reaction that provides the reducing power necessary for the primary reaction of reduction. The 
auxiliary substrate most widely added to the biotransformations is glucose as well as 2-propanol 
which in the process of producing chiral alcohols is oxidized to acetone as a coproduct of the 
reaction1,2. In this sense, the possibility of carrying biocatalysis reactions with enzymes that need 
cofactors is a huge advantage if you are working with whole cells. Indeed, these processes with 
respect to processes with isolated enzymes do not require cofactor recirculation systems and offer the 
ability to selectively synthesise the target molecules using large, abundant and low cost raw materials. 
However, these systems, though advantageous, require expensive and time consuming equipment. In 
some cases, the development of uncontrolled metabolic processes during cell growth, with the 
production of toxic products for cells, sometimes makes it difficult to separate products from the rest 
of cell culture3. 
ESTERASE AND LIPASE 
Esterases and lipases are generally employed in stereospecific hydrolysis, transesterification, ester 
synthesis and other organic reactions.  
The hydrolases (EC 3 -...) form a group of enzymes capable of catalysing the hydrolysis of a covalent 
bond between a carbon atom and a heteroatom by water intervention. Their natural function is purely 
"digestive". Precisely because of the need to hydrolyse a wide variety of nutrients, this family includes 
several enzymatic groups often associated with a wide substrate specificity4. 
Carboxyesterases (EC 3.1.1-) belong to this group of enzymes, and catalyse hydrolysis and the 
formation of ester bonds; they are classified in two enzymatic classes: lipases (EC 3.1.1.3) and 
properly esterases (EC 3.1.1.1), which differ in some catalytic properties5: 
 Lipases preferably catalyse hydrolysis of non-soluble water esters such as long chain fatty 
acid triglycerides, while esterases hydrolyse low molecular weight and water soluble esters. 
 Esterases follow Michaelis-Menten kinetics6, while lipases are active on the organic water-
substrate interface and therefore they  need a minimum substrate concentration for enzymatic 
activity: this phenomenon is known as "interface activation" and, thanks to structural studies, 
has been correlated with the presence of a hydrophobic domain that renders the active site 
inaccessible to the substrate; only in the presence of a minimal concentration of a hydrophobic 
molecule (the substrate itself or an organic solvent) the "lid" moves to show a conformational 
change able to access the substrate at the active lipase site7,8. 
 Finally, while lipases generally show high enantioselectivity, especially to secondary 
alcohols, and organic solvent stability, esterases have greater variability in these two 
characteristics and are generally poorly active in organic solvents. 
 
ω-TRANSAMINASE 
The topic of ω-ATA was already introduced in previous chapters. A focus on two of these enzymes 
widely studied and applied in biocatalytic conversion is presented here.  
The ω -ATA from Chromobacterium violaceum DSM30191 which was described for the first time 
by Kaulmann et at.9 shows 38% sequence identity to the V. fluvialis JS17 enzyme and resembles the 
latter in its preference for aromatic amine substrates. In fact, studies on the CV2025 ω-ATA from C. 
violaceum showed a very broad substrate specificity especially with respect to amine acceptors. The 
production of chiral arylic aminodiols from prochiral ketodiols looks promising and at present we are 
exploring possibilities to optimise ketodiol conversion by the native enzyme. 
On the other hand, Halomonas elongata enzyme (HEWT) was recently characterised by Cerioli et 
al.10 with interesting results. The ω-ATA from this moderate halophile bacterium tolerated 20% (v/v) 
co-solvents over 22 h, the best solvents were MeOH (47%) and DMSO (27%). Acceptance of 
isopropylamine as amino donor is an advantage in asymmetric synthesis and a cost-effective benefit 
for industrial applications. With its high enantioselectivity, large substrate spectra and stability in 
organic solvents, HEWT is a promising enzyme for biotechnological applications in the production 
of chiral amines. 
PROJECT AIM 
In order to understand the possible biocatalytic applications on pramipexole intermediates, a new 
approach was investigated. Some more common and terrestrial recombinant enzymes were screened 
for the achievement of optically pure pramipexole precursor. 
A recombinant non-marine ketoreductase from Pichia glucozyma (KRED1-Pglu)11–13 used for the 
enantioselective reduction of various cyclic ketones was applied on pramipexole ketone intermediate 
by using co-factor recycling system. 
Another enzymatic activity was investigated in order to achieve optically pure intermediates for the 
preparation of both pramipexole enantiomers. Five of the most common commercial lipases and one 
new recombinant esterase from Bacillus coagulans14 were tested on pramipexole ester intermediates. 
Lastly, Chromobacterium violaceum and Halomonas elongata ω-transaminases were screened for 
biocatalytic conversion of pramipexole intermediates. 
 
RESULTS 
KETO-REDUCTASE 
Starting from the very promising results obtained with the novel recombinant keto-reductase from 
the non-common terrestrial yeast Pichia glucozyma (KRED1-Pglu) on a wide range of aromatic 
ketones, the idea was to check this reductase activity on the keto-intermediate of pramipexole. The 
employment of this recombinant enzyme has allowed the achievement of the alcohol intermediate 
with opposite stereochemical outcome in comparison with S. cerevisiae whole cells (scheme 4.1 and 
table 4.1). 
 
Scheme 4.1. Recycling of cofactor employing KRED1-Pglu and a glucose dehydrogenase (GDH)15. 
 
Time (h) Conversion (%) e.e.(%) Configuration 
4 75 86 S 
Table 4.1.  KRED1-Pglu-catalyzed bioconversion of pramipexole keto intermediate by using a cofactor recycling 
system. 
ESTERASE AND LIPASE  
Based on former studies not already published on a new recombinant esterase from Bacillus 
coagulans (BCE), a benzoyl ester was synthesized in order to verify the enantioselective hydrolysis 
by BCE. Moreover, a commercial esterase active on benzoyl esters was assayed: pig liver esterase 
PLE (scheme 4.2 and table 4.2). 
 
Scheme 4.2. Bioconversion of the benzoyl ester intermediate into alcohol intermediate and benzoic acid. 
ESTERASE 
24h 
Conversion (%) e.e.(%) Configuration 
BCE 12 100 R 
PLE - - - 
 
Table 4.2. BCE- and PLE-catalyzed conversion. 
For what concerns lipase activity, 5 commercial lipases as Pseudomonas fluorescens lipase (PFL), 
Candida antarctica lipase A and B (CAL A, CAL B), lipase from porcine pancreas (PPL) and from 
Candida cylindracea (CCL) were screened toward the acetyl ester intermediate of pramipexole 
(scheme 4.3 and table 4.3). The use of commercial lipases showed a high activity on this substrate 
but low molar conversion percentages, although the high e.e. with R-isomer preference like BCE. 
 
Scheme 4.3. Bioconversion of acetyl ester intermediate into alcohol intermediate and acetic acid. 
LIPASE 20h Conversion (%) e.e.(%) Configuration 
CAL A-CLEA* 5 80 R 
CAL B 49 71 R 
PFL 5 100 R 
PPL 7 100 R 
CCL 9 20 R 
Table 4.3. Biotransformation molar conversion and enantiomeric excesses. *CLEA stands for cross-linked 
enzyme aggregates (CLEA Technologies). 
ω-TRANSAMINASE 
The application of H. elongata (HEWT) and C. violaceum (CV2025) ω-ATAs was exploited in 
bioconversion of pramipexole keto intermediate with (S)-1-phenylethylamine ((S)-1-PEA) and L-
alanine as amine-donor (scheme 4.4). With both recombinant enzymes, no conversion of substrate 
has been seen. 
 
Scheme 4.4. Transaminase catalysis on pramipexole intermediate. 
MATERIALS AND METHODS 
MATERIALS 
All reagents and solvents were obtained from Sigma–Aldrich-Fluka and used without further 
purification or drying. TLC was performed with Merck silica gel 60 F254 pre-coated plates. Silica 
gel column chromatography was performed on silica gel 60 (40–63 mm particle size). Pramipexole 
keto intermediate (2-acetylamino-6-oxo-4,5,6,7- tetrahydrobenzothiazole) was prepared following a 
procedure previously described16.  
Commercial enzymes were employed following the patent WO 2006012277 A217 and the work by 
Ferraboschi et al18–20. Lipase from porcine pancreas (PPL, 23.9 U/mg), Candida cylindracea lipase 
(CCL, 3.86 U/mg), Pseudomonas fluorescens (PFL, 40.2 U/mg), Esterase from porcine liver (PLE, 
≥15 U/mg) and Candida antarctica lipase B (CAL B, 5 U/mg) were purchased by Sigma-Aldrich. 
Candida antarctica lipase A CLEA (CAL A CLEA, 1.56 U/mg) was obtained from CLEA 
Technologies.  
CHARACTERISATION  
Nuclear magnetic resonance (NMR) spectra were recorded at 300 K on a Bruker-Avance 500 MHz 
spectrometer operating at 500.13 and 125.76 MHz for 1H and 13C acquisitions, respectively. Chemical 
shifts (δ) of the 1H NMR and 13C NMR spectra are reported in ppm using the signal for residual 
solvent proton resonance as the internal standard (1H NMR: CDCl3 7.26, DMSO-d6 2.49, CD3OD 
3.31 ppm; 13C NMR: CDCl3 77.0 (central line), DMSO-d6 39.50 (central line), CD3OD 49.00 (central 
line) ppm). HPLC analyses were performed by using a Jasco Pu-980 equipped with a UV/Vis detector 
Jasco UV-975. Chiral HPLC columns used: Chiralpak IA (4.6V250 mm, 5 mm, Daicel), Optical 
rotatory power determinations were performed by a Perkin–Elmer (mod. 241) polarimeter in a 1 dm 
cell at 20 °C, setting the wavelength at 589 nm or at 546 nm.   
 
KETO-REDUCTASE 
KRED-Pglu was kindly provided by Professor Francesco Molinari’s research group (University of 
Milan, DEFENS department, Milano, Italy). Recombinant GDH from Bacillus megaterium was 
kindly provided by Prof Daniela Monti (Istituto di Chimica del Riconoscimento Molecolare, C.N.R., 
Milano, Italy). 
BIOTRANSFORMATIONS 
Molar conversion and enantioselectivity were determined using an enzyme-coupled system with 
glucose-glucose dehydrogenase (GDH) from Bacillus megaterium15 for cofactor recycling.  
Reductions were carried out in 5-mL screw-capped test tubes with a reaction volume of 1 mL with 
KRED1-Pglu (20 mU/ mL), GDH (1 U/mL), NADP+ (0.1 mM), substrate (1 g/L), glucose (4×mmol 
of substrate) suspended in 50 mMTris-HCl buffer pH 8.0. The biotransformation was kept under 
stirring at 30 °C for 24 h. 
Although the pH suitable for pramipexole ketone intermediate bioconversion is around pH 5-6, 
KRED1-Pglu is able to catalyse alcohol production with high rate avoiding substrate degradation.  
For extraction, EtOAc was added in each sample collected at various time for monitoring conversion 
and the resulting mixture was shaken and centrifuged; the organic phases were collected, dried under 
N2 and analysed by HPLC. 
 
ESTERASE AND LIPASE 
BCE was kindly provided by Prof. Francesco Molinari’s research group (University of Milan, 
DEFENS department, Milano, Italy).  
ESTER SYNTHESIS  
For what concerns the acetyl ester, the procedure described by Ferraboschi et al.16 was followed. For 
the preparation of pramipexole benzoyl ester intermediate, 6-hydroxy derivative was treated with 
benzoyl chloride in pyridine. 
BIOTRANSFORMATIONS 
Benzoyl ester hydrolysis was carried out in 2 mL Eppendorf tubes with a reaction volume of 1 mL 
with BCE (20 mU/ mL), substrate (0.1 g/L) suspended in 50mMTris-HCl buffer pH 8.0, NaCl 100 
mM. The biotransformation was kept under stirring at 30 °C for 24h.  
DMSO as co-solvent was not employed in order to avoiding keto substrate degradation. 
Acetyl ester hydrolysis, instead, was performed in 10-mL screw-capped test tubes with a reaction 
volume of 3 mL with the proper amount of commercial lipases17,19,18,20, H2O (5×mmol of substrate), 
substrate (20 mM) suspended in acetonitrile (ACN). The biotransformation was kept under stirring at 
30 °C for 24h. 
For extraction, EtOAc was added in each sample collected at various time for monitoring conversion 
and the resulting mixture was shaken and centrifuged; the organic phases were collected, dried under 
N2 and analysed by HPLC. 
 
ω-TRANSAMINASE 
During this experimental work, we had the opportunity to test aminotransferase potential of 
Chromobacterium violaceum and Halomonas elongate ω-ATAs on keto intermediate of pramipexole 
synthesis.  
Both enzymes were kindly provided by Prof. Francesca Paradisi’s research group. 
BIOTRANSFORMATIONS 
The enzymatic reactions were carried out at 37 °C in 100 mM potassium phosphate buffer pH 8.0, 
0.1 mM PLP using a purified enzyme solution (0.25 U/mL). The reaction mixture contained 10 mM 
(S)-1-PEA or 10 mM L-alanine and 10 mM pramipexole keto intermediate as amine-acceptor in a 
reaction volume of 200 μL. 
For HPLC analysis, samples were collected at different time, diluted 1:50 with HCl 0.2% solution for 
quenching the reaction and injected. 
 
PURIFICATION AND CHEMICAL CHARACTERISATION 
 2-Acetylamino-6-hydroxy-4,5,6,7-tetrahydrobenzothiazole 
The reaction progress and ee were determined by using HPLC using a Chiralpak IA column (n-
hexane/iPrOH 8:2 as eluent, flow rate: 0.7 mL min−1, 254 nm), tr (R)-2 i 10.9 min, tr (S)-2 i 14.8 min.16 
Yellowish solid. Rf=0.25 (CH2Cl2/MeOH, 95:5). ee=64 %. 1H NMR (300 MHz,CD3OD): δ=1.91 
(dddd, J=14.2, 8.6, 7.7, 5.9 Hz, 1 H), 2.04 (dddd, J=14.2, 6.2, 5.9, 2.9 Hz, 1 H), 2.26 (s, CH3, 3 H), 
2.61–2.71 (m, 2 h), 2.79 (dddd, J=16.5, 5.9, 5.9, 1.8 Hz, 1 H), 2.99 (ddd, J=15.7, 4.7, 1.8 Hz, 1 H), 
4.15 ppm (dddd, J=8.6, 6.9, 4.7, 2.9 Hz, 1 H); 13C NMR (300 MHz, CD3OD): δ=21.2, 23.2, 30.5, 
30.7, 66.2, 120.9, 143.2, 156.4, 169.1 ppm; elemental analysis calcd (%) for C9H12O2N2S (212.06): 
C 50.92, H 5.70, N 13.20; found: C 50.96, H 5.89 N 12.85. 
2-Acetylamino-6-hydroxy-4,5,6,7-tetrahydrobenzothiazole, 6-benzoate 
HPLC analysis: Chiralpak IA, hexane/2-propanol 8:2 as eluent, flow rate 0.7 mL/min. Rt (R)-isomer 
14.32 min; (S)-isomer 16.25 min. 1H NMR (CDCl3): δ 8.02 (2H, d, J = 8.0 Hz, o-Ph H), 7.58 (1H, t, 
J = 8.0 Hz, p-Ph H), 7.46 (2H, dd, J = 8.0, 8.0 Hz, m-Ph H), 5.58 (1H, dddd, J = 7.6, 5.5, 4.8, 2.5 Hz, 
6-H), 3.20 (1H, ddd, J = 16.5, 4.8, 1.2 Hz, 7a-H), 3.02 (1H, dd, J = 16.5, 5.5 Hz, 7b-H), 2.93 (1H, 
ddd, J = 16.8, 8.4, 5.9 Hz, 4a-H), 2.86 (1H, dddd, J = 16.8, 6.2, 5.8, 1.4 Hz, 4b-H), 2.30 (3H, s, CH3), 
2.30 (1H, dddd, J = 13.5, 7.6, 5.9, 5.8 Hz, 5a-H), 2.00 (1H, dddd, J = 13.5, 8.4, 6.2, 2.5 Hz, 5b-H). 
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BACKGROUND 
ω-TRANSAMINASE 
Although the transaminase potential is under a magnifying glass since decades, their applicability in 
biotechnological fields for the preparation of chiral amino compounds is not entirely exploited yet. 
Combining ATAs with other enzymatic or chemical routes has been demonstrated to be a smart 
method for practical applications, particularly in regard to shortening the reaction routes, avoiding 
protecting steps, reducing chemical waste and achieving a high atom-efficiency1–3. 
This makes these enzymes useful for synthesis of chiral amines, which are of high importance as 
building blocks for production of optically pure amino synthons in pharmaceutical like sitagliptin4, 
ethambutol5, imagabalin6, norephedrine and pseudoephedrine7, food, agrochemical and cosmetic 
additives8. 
Synthesis by ATAs suffers from the unfavourable reaction equilibrium, especially in the asymmetric 
synthesis of amines from an amino acid as amino donor9. To maximize the productivity of ATAs, 
shifting the equilibrium to the side of product is extremely important10,11. Equilibrium displacement 
has been done by removal of the products or large excess of amino donor12,13.  
Nevertheless, maintaining the quaternary and tertiary structures under non-physiological conditions 
(high concentrations of substrate and product, organic solvent, mechanical force, etc.) for a long 
period of time (10–100 h working time and an even longer storage time) is a huge task for all 
biocatalysts. The current trend in this research field is directing to the identification and designing of 
new ω-transaminases with defined substrate specificity and capable of adapting to the uncommon 
catalytic conditions of industrial processes. 
 
SOLUBILITY ISSUE 
Protein overexpression systems, such as the E. coli T7 system, have been widely used for protein 
purification. However, due to improper folding of the overexpressed proteins, they often aggregate 
to form inclusion bodies, greatly reducing the protein yield. Different methods have been used to 
solve this problem14, such as optimization of bioprocess parameters or using dedicated screening tools 
for finding conditions for soluble expression15, expression at reduced temperature16, solubility-
enhancing fusion tags17,18, co-expression of chaperones19, consideration of codon usage20 and 
refolding of proteins after dissolving inclusion bodies in denaturing reagents21–23 (fig. 5.1).  
 
Fig. 5.1. All these methods were taken into account and the results illustrated below. 
Solubility on overexpression of some proteins has been found to be altered by certain mutations24. 
Individual mutations differ in the extent to which they influence the solubility on overexpression. For 
example, the W131A and V165K mutants of human HIV type 1 integrase are only marginally more 
soluble, whereas the F185K is significantly more soluble relative to the wild-type under the same 
conditions of overexpression25.  
Systematic replacement of hydrophobic residues has also been attempted, but only some of these 
mutations resulted in improved solubility25–27. Mutations involving substitution of less polar residues 
with more polar ones, identified by multiple sequence alignment of the insoluble protein with related 
soluble proteins27 or predicted solvent accessibilities28 have also been attempted, but only some 
mutations have manifested in improved solubility. Many of these types of mutations are identified by 
random mutagenesis procedures29,30. Asano et al.31, have created highly active and in vivo soluble 
mutants of MeHNL1 (hydroxynitrile lyase from Manihot esculenta, cassava plant) in E. coli by 
directed evolution, where several mutants of this enzyme were generated including His103 and also 
Lys-Pro mutants. 
There are other examples of correlation between one single point mutation and folding changing. 
Particulary, regarding human transaminases, some specific mutations such as P11L (major allele) and 
G47R (minor allele) on alanine:glyoxylate aminotransferase (AGT) was proved to have a role in  
misfolding and pathogenic aggregation leading to Primary Hyperoxaluria Type I. These mutations 
seem to be involved in dimerization and stabilization of enzyme complex32,33. 
MUTAGENESIS  
In recombinant applications, high levels of soluble expressed protein are usually required and often 
this entails an alteration of the physiological requirements for the enzyme natural folding leading to 
the formation of inclusions bodies. Therefore, thinking about a solubility improvement of enzyme 
sequences could be more than appreciable but not universally possible through a rational strategy. 
Moreover, utilization of proteins outside of their usual biological context, for example in industrial 
applications, often requires improvement of biophysical properties such as stability34,35. In the 
Introduction the mutagenesis strategies aimed at solving this issue were already presented.  
Another approach based on multiple sequence alignments (MSAs) consists in statistical amino acid 
frequencies analysis36,37. Data-driven mutagenesis design is based on the simple assumption that the 
frequency of a given residue in an MSA of homologous proteins correlates with that amino acid's 
contribution to protein stability38–40. A de novo designed protein possessing the most frequent residue 
at each position should accordingly show maximum stability. Given the difficulty of predicting how 
individual residues contribute to overall stability41, this approach to protein stabilization is often 
preferable to classical rational design or is adopted as a complement of it, particularly as it does not 
depend on the availability of structural information.  
 
PROJECT AIM 
The present work descibes the attaining of soluble expression of a novel ω-transaminase from a newly 
isolated halotolerant marine bacteria Virgibacillus pantothenticus(VPTA). This marine bacterium is 
part of the micro-biodiversity of Deep Hypersaline Anoxic Basins on the Mediterranean Ridge, a new 
and uncommon source of biocatalysts. Despite of several standard methodologies applied, the marine 
wild-type enzyme VPTA was total insoluble in E. coli host and it was satisfactorily solubilized by 
one single-point mutation, allowing the characterization of the new ω-transaminase. Combining 
statistical amino acid frequencies analysis with a rational approach based on 3-D model, a target 
residue likely involved in structural stabilization and dimerization was selected. This finding has 
significant implications for ω-transaminase structure-stability-solubility understanding and 
represents one of the first works about semi-rational approach aimed at improving recombinant ω-
ATAs solubility allowing the characterization of this new halotolerant ω-ATA. The enzyme shows 
an interesting salt and solvent tolerance in accordance to its origin and it results particularly active 
toward interesting building blocks.  
 
RESULTS AND DISCUSSIONS 
WILD-TYPE VPTA AND SOLUBILISATION STRATEGIES 
The protein sequences of the Vibrio fluvialis, Chromobacterium violaceum and Halomans elongata 
ω-ATAs were used to search for homologous proteins with the BLAST search option of Rast server 
at default settings. H. elongata ω-ATA alignment showed the best results coming up with a sequence 
identity of 38% and similarity of 55%; with V. fluvialis and C. violaceum enzymes the similarity 
percentage was 36%. Rast annotation42 describes this candidate as “omega-amino acid-pyruvate 
aminotransferase [EC 2.6.1.18]”, a member of the pyridoxal phosphate (PLP)-dependent aspartate 
aminotransferase superfamily (fold I)43.  The selected gene is 1350 bp expressing a 448 residues wild-
type protein. From the sequence alignment it was possible to identify the three residues considered to 
be responsible for the transaminase catalytic activity (figure 5.2):  
 D244Aspartic acid: salt bridge/H-bond to N1 of pyridoxal 5’-phosphate; 
 K273 Lysine: Schiff base with pyridoxal 5’-phosphate; 
 R402 Arginine: salt bridge/H-bond with α-carboxylate group of substrate.  
 
Fig. 5.2. Representation of small and large binding pockets of VPTA. Main residues involved in PLP and 
substrate interactions are showed44. 
 
The nucleotide sequence was cloned in a classical E. coli BL21 DE3 expression system through 
Champion™ pET100/pET101 Directional TOPO™ Expression Kit with His-tagged tail in N-
terminal and C-terminal respectively. Standard expressions in the E. coli strains BL21 DE3, BL21 
DE3 star, Rosetta, Codon plus RIPL and also a co-expression with pGKJE8 plasmid (Takara 
Clonetech) coding for most common chaperones resulted in inclusion bodies accumulation with no 
soluble protein production (figure 5.3). Better results were not achieved with protein refolding and 
cell-free expression (figure 5.3). The halophilic archaea host Haloferax volcanii was also exploited 
for the expression of the marine transaminase (figure 5.3) without any improvement45.  
  
 
 
 
 
 
 
Fig 5.3. Wild-type VPTA has a molecular weight of 53 kDa; Marker 50 kDa band is underlined by arrows. 
Enzyme expression studies exploiting different strategies. Cold shock method with BL21 DE3 and Codon Plus 
RIPL E. coli strains (a); denaturation with urea and refolding (b); cell-free (c) and Haloferax volcanii expression 
(d). 
Generally, the total expression level was always high in all the conditions, although to a different 
extent. Unfortunately, in  all cases, the enzyme was obtained in insoluble form. Although soluble 
protein seems to be present in cell-free expression method and in H. volcanii expression, the kinetic 
assay by Schatzle et al.46 showed no transaminase activity on these soluble fractions. 
a b 
c 
d 
MUTAGENESIS 
Starting from ConSurf47 analysis in which 500 homologous sequences were compared getting a 
statistical frequency (table 5.1) and a level of conservation (figure 5.4) for each position, some 
residues less conserved than the catalytic one were taken into account.  
 
 
 
 
 
 
 
 
 
Table 5.1. ConSurf results 
in terms of statistical amino acid frequency for each position. In the table, only the first 20 positions are shown as 
an example. 
 
POSITION 
AA with the HIGHEST 
FREQUENCY 
% FREQUENCY 
1 M 100 
2 N 38 
3 S 37 
4 L 88 
5 Q 29 
6 E 35 
7 L 59 
8 D 88 
9 A/R 23 
10 A 38 
11 H 88 
12 H 41 
13 L 52 
14 H 88 
15 P 97 
16 F 45 
17 T 49 
18 D 31 
19 L 14 
20 K 34 
  
Fig. 5.4. Conservation scale by ConSurf on VPTA amino acidic sequence. The position 16 shows a quite high 
conservation. 
 
After target residues localization in tertiary structure model, threonine in position 16 was selected. 
Position 16 has a good level of conservation but the residue with the highest frequency in that position 
is phenylalanine (T16F). 
The protein model was built using the SWISS-MODEL Homology Modeling tool48, superimposing 
the VTPA protein sequence on the resolved structure of the homologous amino transaminase from 
Vibrio fluvialis (PDB: 4E3Q). The result elaboration and the structural evaluation was achieved using 
the molecular visualization system PyMOL (open source license). Sequence analysis and alignment 
was performed with CunSurf, a software for multiple blast provided by BioSoft.    
b 
Fig. 5.5. VPTA  model with threonine in yellow. This residue is localised on a small loop at N-terminal in a 
distinct motif above the catalytic K in light blue (a); the homodimerisation (b) involves hydrophobic amino acids 
(red) from both monomers in what is called hydrophobic pocket (d). In binding pockets of V. fluvialis ATA many 
hydrophobic residues are present (c) likely with a role in dimer formation. 
The mutation choice reflects the current positions in regard to this residue involved in the active site 
with no particular predisposition to central catalytic role6,40,44,49, despite of proximity to substrate 
binding pocket and moderately high level of conservation of the positions (ConSurf analysis figure 
5.4). The amino acids involved with high probability in the structural stabilization of the functional 
homodimer are less conserved than the catalytic ones at least, but they are preserved by evolution 
anyway. This could shed light on the structural role of this residue in the ω-ATAs homodimerization 
and stabilization. 
 
VPTA T16F 
The expression of the N-terminal his-tagged transaminase was performed and compared in different 
conditions and best results were achieved with ZYM-5052 auto-induction medium at 150 rpm, at 30 
°C for 24 h. Purification was performed by immobilized metal affinity chromatography (IMAC). The 
enzyme was obtained in the pure form, expressed at higher concentration in auto-induction medium 
with a specific activity 2.4 U/mg and a volumetric yield 4 mg/L (figure 5.6).  
 
a 
c 
d 
 Fig. 5.6. VPTA T16F SDS-PAGE purifications fractions from auto-induction expression. The purified fractions 
present the molecular weight attended (53 kDa). 
 
EFFECT OF pH AND TEMPERATURE  
VPTA preparation was suspended in a universal buffer solution at the desired pH and stored at 4 °C 
for 24 h. After incubation, the residual activity was determined with the spectrophotometric enzyme 
assay in standard condition46 (figure 5.7). Only at pH 8 the enzyme is stable and active. 
 
Fig. 5.7. Stability test at different pH: data are reported as relative percentages in comparison with the control in 
standard conditions. Every reaction was performed in three replicates and the results are reported as the average of 
the data obtained. 
50 kDa 
Thermal stability was tested after incubation of the enzyme at variable temperatures. After 20 h the 
enzyme mantains 80% of initial activity up to 45 °C.  
The activity was determined with the spectrophotometric enzyme assay performed at the indicated 
temperature. The highest activity was reached between 25 °C and 45 °C. 
      
Fig. 5.8. The X axis shows the set of temperature selected while on Y axis the residual activity in percentage is 
reported. Left panel: stability test of VPTA in the range 25-60 °C. Right panel: activity test of VPTA in the range 
25-60  °C. Each reaction was performed in triplicate. Results are reported as the average of the data obtained. 
As described for the first time by Ikai et at.50, this high mesophilic profile could be confirmed by the 
VPTA high aliphatic index of 94.44 (ProtParam tool, accessible from the ExPASy website 
www.expasy.ch). 
EFFECT OF CO-SOLVENTS AND SALTS 
The use of co-solvents is very useful if the bioconversion deals with a very low soluble substrate, for 
this reason the effect of different co-solvents on VPTA activity and stability was investigated. The 
stability analysis was carried out incubating the enzyme with 10% and 20% of a selection of common 
water-miscible organic solvent for 45 h (figure 5.9). In all cases, a decrease in enzyme activity was 
observed, even if VPTA shows a higher stability than HEWT under the same condition. With regard 
to the activity in presence of co-solvents, the best results were obtained with MeOH 10%. Hence, this 
enzyme is suitable for enantioselective amination of ketones and aldehydes where the presence of a 
co-solvent is necessary.  
 Fig. 5.9. The X axis shows the set of solvents selected while on Y axis the residual activity in percentage is 
reported. Left panel: stability test of VPTAwith 10 and 20% solvents after 45 h. Right panel: activity test of 
VPTAwith 10 and 20% solvents. Each reaction was performed in triplicate. Results are reported as the average of 
the data obtained. 
The effect of different salt (NaCl and KCl) concentrations on enzyme stability and activity was also 
investigated. Under activity test conditions in the presence of salts, enzyme activity is very low, when 
compared to the enzyme at pH 8.0 in 50 mM phosphate buffer (figure 5.10). On the other hand, 
incubation of the enzyme in the presence of salts for seven days resulted in a satisfactory residual 
activity only when 1 M KCl was used.  
 
Fig. 5.10. The X axis shows the set of salts selected while on Y axis the residual activity in percentage is reported. 
On the left stability test: incubation was carried out at the indicated salt concentration for 45 h at 4 ◦C. On the 
right activity test in presece of salts: the residual activity of the enzymatic solution was determined by the standard 
spectrophotometric assay carried out in presence of the salt concentration indicated and expressed in function of 
the activity under standard conditions. Every reaction was performed in three replicates and the results are 
reported as the average of the data obtained. 
 
AMINO DONORS 
A number of amino donors was investigated in order to understand the catalytical potential of VPTA 
and consequently its possible applications (table 5.2). VPTA does not display an activity for classical 
amino donors (i.e., L-alanine isomolar with amino acceptor higher than that of HEWT, CV2025 and 
V. fluvialis ω-ATA. However, VPTA shows to be highly (S)-selective showing no detectable activity 
on (R)-(-)-1-phenylethylamine. The final conversion was determined after 24 h of reaction time. 
AMINO DONOR STRUCTURE FINAL CONVERSION (%) 
rac-1-phenylethylamine 
 
43 
S-(-)-1-phenylethylamine 
 
71 
R-(-)-1-phenylethylamine 
 
/ 
Isopropylamine* 
 
/ 
benzylamine 
 
47 
β-alanine* 
 
/ 
L-alanine* 
 
8 
D-alanine* 
 
/ 
cinnamyl-amine 
 
74 
3,4-(methylenedioxy)benzylamine 
 
70 
vanillylamine 
 
90 
putrescine*  / 
cadaverine*  / 
4-phenylbenzylamine 
 
16 
Table 5.2. VPTA specificity on different amino donors are reported. The enzymatic reactions with VPTA were 
carried out as reported in Materials and Methods. Every reaction was performed in three replicates and the results 
are reported as the average of the data obtained. Concentration of amino donors was kept constant at 10 mM, as 
amino acceptor 10 mM pyruvate was normally employed, except for the substrate with *, where pyruvate was 
substituted with10 mM benzaldehyde. The substrate was added in methanol solution to guarantee the correct 
concentration of the substrate in reaction mixture (final concentration 10% MeOH). Final conversions with VPTA 
were determined by HPLC analysis as reported in materials and methods. 
AMINO ACCEPTORS 
VPTA shows no interesting activity on standard amino acceptors in comparison with HEWT, 
CV2025 and V. fluvialis ω-ATA. Some promising conversions resulted for substrates such as 
phenylacetaldehyde, cinnamalaldehyde, biphenyl-4-carboxaldehyde and 3-phenylpropionaldehyde 
(table 5.3). These bulky aldehydes are well accepted by the enzyme. The lack of activity with D-
fructose and L-ribulose could be caused by a steric clash hampering the accomodation of the substrate 
in the catalytic pocket. The final conversion was determined after 24 h of reaction time. 
AMINE ACCEPTOR STRUCTURE FINAL CONVERSION (%) 
pyruvic acid* 
 
71 
β-hydroxypyruvic acid* 
 
/ 
glyoxylic acid* 
 
/ 
benzaldehyde 
 
49 
phenylacetaldehyde 
 
90 
2-phenylpropionaldehyde 
 
53 
vanillin 
 
/ 
cinnamalaldehyde 
 
93 
cyclohexanone* 
 
/ 
1,3-dihydroxyacetone* 
 
/ 
L-erythrulose* 
 
/ 
L-ribulose* 
 
/ 
D-fructose* 
 
/ 
4-nitrobenzaldehyde 
 
50 
3-nitrobenzaldehyde 
 
86 
2-nitrobenzaldehyde 
 
68 
biphenyl-4-carboxaldehyde 
 
81 
3-phenylpropionaldehyde 
 
91 
Table 5.3. VPTA specificity with different amino acceptors are reported. The enzymatic reactions with VPTA 
were carried out as reported in materials and methods. Every reaction was performed in three replicates and 
results reported as the average value. Concentration of amino acceptors was kept constant at 10 mM, as amino 
donor 1 M L-alanine was normally employed, except for the substrate with *, where L-alanine was substituted 
with 50 mM (S)-PEA. The substrate was added in 10% methanol solution to guarantee the correct concentration of 
the substrate in reaction mixture. Final conversion with VPTA were determined by HPLC analysis as reported in 
materials and methods. 
 
ENZYME KINETICS 
The maximum velocity (Vmax) was 0.19 µM/s and the Michaelis–Menten constants (Km) were 1.9 
mM and 10.7 mM for (S)-(–)-1-phenylethylamine and pyruvate, respectively. The turnover number 
was also determined as kcat 0.099 s
−1 (figure 5.13).  
 
Fig. 5.13. Comparison between HEWT and VPTA kinetic parameters. 
 
MATERIALS AND METHODS 
Unless stated otherwise, all chemicals and media components were purchased from Sigma-Aldrich 
(Steinheim, Germany), New England Biolabs  (Ipswich,  MA,  USA)  or  Merck  (Darmstadt,  
Germany), Fisher BioReagents (Loughborough, United Kingdom). Primers and sequencing were 
furnished by Eurofins MWG Operon (Ebersberg, Germany). Plasmid pG-KJE8 harboring 
Chaperonins was from Takara Clontech (Saint-Germain-en-Laye, France). Champion pET100 
Directional TOPO Expression Kit and QuikChange Lightning Site-Directed Mutagenesis Kit were 
provided respectively by Invitrogen (Loughborough, United Kingdom) and Agilent Technologies 
(Santa Clara, CA, USA).  
MARINE MICROORGANISM, GENE IDENTIFICATION AND 
CLONING 
Virgibacillus pantothenticus marine bacterial strain (EMBL database accession numbers HG799644) 
belongs to the European project Biodeep collection isolated from water-brine interface of the deep 
hypersaline anoxic basin Discovery (35° 17′ N, 21° 41′ E), on the Mediterranean Ridge 51. Due to the 
high halotolerant features52, Virgibacillus pantothenticus genome was selected for sequencing, the 
data were deposited in The Seed database and genes were annotated by RAST software42 (Rapid 
Annotation using Subsytems Technology). 
Virgibacillus pantothenticus was grown in CYSP medium (casitone 15 g/L, yeast extract 5 g/L, 
soitone 3 g/L, peptone 2 g/L, MgSO4*7H2O 15 mg/L, FeCl3*6H2O 116 mg/L, MnCl2*4H2O 20 mg/L, 
NaCl  30 g/L) at 30° C 53. After 24 h the cells in stationary phase were harvested and genomic DNA 
was extracted with GenElute Bacterial Genomic DNA Kit (Sigma-Aldrich). 
VPTA gene was identified by homology blasting Chromobacterium violaceum, Vibrio fluvialis and 
Halomonas elongata transaminase amino acidic sequences on V. pantothenticus genome at default 
settings of RAST software. All the three enzyme sequences match with the gene annotated as omega-
amino acid-pyruvate aminotransferase. The gene was cloned in pET100, pET101 plasmid employing 
Champion pET Directional TOPO Expression Kit. 
EXPRESSION OF WILD-TYPE VPTA 
Expression of the recombinant VPTA protein was performed using BL21 DE3, BL21 DE3 star, 
BL21(DE3), Rosetta, Codon Plus RIPL E. coli strains and pET100, pET101 expression vectors (His 
tag respectively in N-terminal and C-terminal). A following transformation with pG-KJE8 plasmid 
allowed the co-expression of VPTA with the chaperonins dnaK, dnaJ, grpE, groES, groEL following 
the protocol provided by Takata Clontech. Expression cultures were prepared growing a single colony 
of E. coli cells carrying the recombinant plasmid for 24h at 18, 25, 30, 37 °C, on a rotatory shaker at 
200 rpm, in flasks containing LB/TB/ZYM-5052 auto-induction medium54 with 100 µg/mL 
ampicillin. For LB and TB medium the IPTG added was 0.5 mM at 0.6 OD of cell growth, with 24 
hours of expression time, unless stated otherwise. Experiments were carried out in 1 L baffled 
Erlenmeyer flasks containing 300 mL of liquid medium. 
MUTAGENESIS ON VPTA 
The VPTA gene harbored in a pET100 plasmid was mutated employing the QuikChange Lightning 
Site-Directed Mutagenesis Kit provided by Agilent Technologies. The oligonucleotide primer was 
designed using the QuickChange Primer Design tool (Agilent Technologies). The T16F mutant was 
achieved using the following primer: 5′-atgttgttgctcttgtatcgatgagaatggatggatgaaatgcttcttatccaac-3′ 
(mutated codon is underlined). 
EXPRESSION OF VPTA T16F 
Expression of the recombinant VPTA protein was performed using BL21 DE3 E. coli strain with 
pET100 as expression vectors. Preliminary trials showed that this host yielded the higher VPTA 
expression as compared to Codon plus RIPL cells. The best expression results were achieved in the 
following conditions: expression cultures were prepared growing a single colony carrying the 
recombinant plasmid in 1L flasks containing 300 mL of auto-induction broth with 100 µg/mL 
ampicillin at 30 ° C, with 180 rpm of stirring, for 24h. Cells were harvested by centrifugation.  
PURIFICATION 
Pellets of 300 mL cultures were suspended in about 12 mL (2 mL per g pellet) of washing buffer (50 
mM Tris-HCl pH8, 100 mM NaCl, 0.1 mM PLP, 30 mM imidazole) and lysed by sonication as 
described before55. The lysate was clarified by centrifugation at 13,000 × g for 1 h at 4°C, filtered 
through a 0.45 μm filter (Millipore, Bedford, MA, USA). Using an ÄKTA Start System (GE 
Healthcare, Little Chalfont, UK), crude extract was loaded at a flow rate of 1 ml/min into a 1mL 
HisTrap HP column pre-charged with NiSO4 (0.1 M). The column was washed at a flow rate of 
1mL/min with at least 10 column volumes of washing buffer and the enzyme was eluted with eluition 
buffer (50 mM Tris-HCl pH8, 100 mM NaCl, 0.1 mM PLP, 300 mM imidazole), after an intermediate 
step with the 15% of elution buffer to remove non-specifically bound proteins. The fractions 
containing the enzyme were desalted via overnight dialysis against 50 mM phosphate buffer pH 8, 
containing 0.1 mM PLP. The purified enzyme was quantified by Epoch Take3 and stored at 4◦C. The 
spectrophotometric enzymatic assays described by Deszsn et al.40 was employed for testing the 
enzymatic activity. The acronym VPTA was adopted to recognize Virgibacillus pantothenticus 
omega-transaminase. Fractions of 0.5 ml were collected, analyzed by SDS-PAGE using a 12% 
polyacrylamide gel. For separation into soluble and insoluble fractions, samples were centrifuged at 
13,000 × g for 1 h at 4°C, and the pellet was suspended in the same volume of 50 mM Tris-HCl buffer 
pH8. 
SDS-PAGE ANALYSIS 
The concentration of the purified protein was determined spectrophotometrically by UV absorption 
at 280nm. The extinction coefficient 40.130 M−1 cm−1, at 280nm, measured in water, was estimated 
by ExPASy ProtParam tool, accessible from the ExPASy website (www.expasy.ch). SDS-PAGE was 
carried out employing a 12% polyacrylamide gels, stained with Coomassie Brilliant Blue R250 and 
a broad range protein marker was used for determination of relative molecular weight. 
SPECTROPHOTOMETRIC ENZYMATIC ASSAY 
A kinetic assay derived from Schatzle et al.46 was used as standard enzymatic assay. The reactions 
were carried out at 25 °C employing a reaction mixture containing 1 mL phosphate buffer (50 mM, 
pH 8), 2.5 mM (S)-(–)-1-phenylethylamine, 2.5 mM pyruvate, 0.25% DMSO, 0.1 mM PLP and a 
proper amount of enzyme. These parameters were modified in order to investigate the behavior of the 
enzyme in different reaction conditions. The activity was estimated following the production of 
acetophenone during the first three minutes of reaction at 245 nm using a Bioteck Epoch Microplate 
Spectrophotometer. In the study of the effect of the pH on enzyme activity and stability, instead of 
the phosphate buffer, a universal buffer was employed. This system contains 25 mM citric acid, 25 
mM KH2PO4, 25 mM Tris, 12.5 mM Na2B4O7, and 25 mM KCl
56.  
VPTA stability at different temperatures was checked with a standard activity assay after enzyme 
incubation at 25, 37, 45, 50, 55, 60 °C for 20h. For what concerns activity studies, the 
spectrophotometric enzymatic activity test was carried on at these temperatures. 
The effect of co-solvents on VPTA stability was studied storing the enzyme in the presence of either 
10 or 20% (v/v) of co-solvent at 4 °C for 45 h. Before and after incubation the residual activity was 
determined by the standard spectrophotometric enzymatic assay. The effect of co-solvents on VPTA 
activity was checked in presence of the corresponding amount of co-solvents in the reaction mixture. 
As done with solvents, stability was tested in presence of different concentrations of NaCl and KCl, 
the residual activity after 7 days was measured by the standard spectrophotometric assay. For activity 
analysis, the kinetic assay was carried on in the presence of salts. Residual activity was measured in 
both cases by the standard spectrophotometric assay. 
 
ENZYMATIC REACTION 
The enzymatic reactions with different amino-donor and acceptors were carried out at 37 °C in 100 
mM phosphate buffer pH 8. In amino-donor screening, the reaction mixture contained 10 mM 
enantiopure amino donor (20 mM if racemic), 10 mM pyruvate or benzaldehyde as amino acceptor 
(see table 5.2) and 0.1 mg/mL of VPTA in a reaction volume of 200 μL (10% MeOH as co-solvent). 
Differently, amino-acceptors screening was carried out with 10 mM enantiopure amino-acceptor (20 
mM if racemic), 1 M L-alanine or 50 mM (S)-PEA as amino-donor (see table 5.3) and 0.1 mg/mL of 
VPTA in a reaction volume of 200 μL (10% MeOH as co-solvent). As a control, the reactions were 
set up as previously described but without the addition of VPTA. One enzymatic unit is defined as 
the amount of enzyme that converts 1 μmol of (S)-(–)-1-phenylethylamine in 1 min in standard 
conditions. For storage conditions, VPTA was stable at 4 °C for ten days without evident loss of 
activity. Data were obtained by averaging the measurements on three independent samples. 
ANALYTICAL METHODS 
SPECTROPHOTOMETRIC ANALYSIS 
The kinetic catalytic constants Vmax and Km were measured at pH 8.0 and 25 °C using Bioteck Epoch 
Microplate Spectrophotometer as described above in the presence of 0.25% DMSO, 0.1 mM PLP and 
an appropriate amount of enzyme (0.1 mg/mL). Reactions were carried out at 2.5 mM pyruvate and 
various concentrations (0.5–5 mM) of (S)-(–)-1-phenylethylamine, at 2.5 mM (S)-(–)-1-
phenylethylamine and various concentrations (2.5–12.5 mM) of pyruvate (figure 5.13). 
Concentrations higher than 5 mM of (S)-(–)-1-phenylethylamine gave significant interference with 
the UV detection signal and for this reason it was kept below saturation conditions. The initial-
velocity data were fitted to the Michaelis–Menten equation using SigmaPlot software (Version 11.0). 
HPLC ANALYSIS 
The final conversion of the different amino acceptor were determined employing a Thermo Scientific 
HPLC instrument equipped with Accucore C18, LC column, Particle size 2.6 microm, diameter 4.6 
mm, length 150 mm. The substrates were detected at 210, 245, 280 nm using the following mobile 
phase A: formic acid (0.1% in water), B: ACN; the gradien eluition method is 15% B (10 min), 
increasing to 80% B (over 8 min), decreasing 15% B (over 2 min) at 25 °C with a flow rate of 1 
mL/min. The depletion of aromatic amines, aldehydes and the formation of acetophenone were 
evaluated by calibration curve. The samples were injected after a dilution of 1:50 with HCl 0.2% in 
the quenching step. The retention times in minutes are: acetophenone (8 min), benzaldehyde (6.3 
min), benzylamine (4.1), cinnamaldehyde (16 min), 1-phenylethylamine (5 min), phenylacetaldehyde 
(14 min), 2-phenylpropionaldehyde (14.5 min), vanillin (1.8 min), 4-nitrobenzaldehyde (14 min), 3-
nitrobenzaldehyde (14 min), 2-nitrobenzaldehyde (15 min), biphenyl-4-carboxaldehyde (18.7 min), 
3-phenylpropionaldehyde (16 min), cinnamyl-amine (9 min), 3,4-(methylenedioxy)benzylamine 
(1.54 min), vanillylamine (5 min), 4-phenylbenzylamine (18.7 min). All samples were quenched with 
HCl 0.2% and then centrifuged before the HPLC analysis.  
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CONCLUSIONS  
 
 
 
 
  
WHOLE CELL SCREENING – MARINE YEASTS 
The stereoselective reduction of structurally different ketones using halotolerant marine yeasts (Meyerozyma 
guilliermondii and Rhodotorula mucilaginosa) was studied using cells grown and bio-converted in seawater. The 
preparation of valuable chemicals through water-saving (bio)processes based on the direct exploitation of seawater 
is a significant step towards sustainable biocatalysis. By choosing a suitable strain, high yields and stereoselectivity 
could be achieved in most cases. Notably, high chemoselectivity and enantioselectivity were observed using R. 
mucilaginosa in the reduction of aromatic β-ketonitriles, which allowed the recovery of the optically pure 
corresponding alcohols; notably, reduction with whole cells of yeasts generally give a mixture of undesired 
products, as observed with M. guilliermondii. Although the examples reported here are still limited to the laboratory 
scale, these results show that freshwater can be replaced by seawater in a whole bio-catalysis process using marine 
yeasts. It can be foreseen that halophilic and/or halotolerant marine yeasts (and more generally halophilic and/or 
halotolerant microorganisms) could be a plentiful source of enzymes to accomplish bio-catalysis in seawater. 
WHOLE CELL SCREENING – MARINE BACTERIA 
Starting from the new synthetic pathway developed by Ferraboschi et al., the possibility of employing 
an omega-transaminase enzyme to convert the ketone directly into optically pure amine intermediate 
was taken into account.  
 
Therefore, thirty-three marine bacteria species were screened to identify a transaminase activity on 
model substrates like pyruvate and racemic methyl benzylamine to produce acetophenone. The 
acetophenone detected in some biotransformations confirms the presence of transaminase activity. 
The best performance was achieved with Virgibacillus pantothenticus that was selected for genome 
sequencing. 
RECOMBINANT ENZYME 
About ketoreductase activity, recombinant enzymes were also employed. A newly isolated 
ketoreductase from the uncommon yeast Pichia glucozyma was able to produce the pramipexole S-
alcohol intermediate with 86% e.e. in four hours. 
Other enzymatic activities were investigated in order to achieve optical pure intermediate for the 
preparation of both pramipexole enantiomers. Some of the most common commercial lipases and a 
new recombinant esterase from Bacillus coagulans were tested on pramipexole ester intermediates 
without achieving optically pure compounds. 
VPTA 
In recombinant applications, high levels of soluble expressed protein are usually required and often 
this entails an alteration of the physiological requirements for the enzyme natural folding leading to 
the formation of inclusions bodies. Therefore, thinking about a solubility improvement of enzyme 
sequences could be more than appreciable but not universally possible through a rational strategy.  
The present work illustrates the attaining of soluble expression of a novel omega transaminase from 
a newly isolated halo-tolerant marine bacteria Virgibacillus pantothenticus. This marine bacterium is 
part of the micro-biodiversity of Deep Hypersaline Anoxic Basins on the Mediterranean Ridge, a new 
and uncommon source of biocatalysts. 
Despite of several standard methodologies applied, the marine wild-type enzyme was total insoluble 
in E. coli host and it was satisfactorily solubilized by one single-point mutation, allowing the 
characterization of the new omega transaminase. The enzyme shows an interesting salt and solvent 
tolerance, in accordance to its origin and it results particularly active on some interesting building 
blocks molecules. 
The constant demand of chiral amines by the Food, Pharmaceutical and Fine Chemical industries has 
made ω-transaminases (ω-ATAs) some of the most interesting biocatalysts of the last decades. The 
research current trend is directing to the identification and designing of new ω-ATAs with defined 
substrate specificity and capable of high stress-tolerance, in order to complement or replace the 
traditional synthetic methods. To date, ω-ATAs biocatalytic potential is not entirely exploited yet, 
despite of remarkable progresses achieved either by random and rational approaches. 
This latter strategy was followed to select a target residue likely involved in structural stabilization. 
Comparison of primary sequences and three-dimensional models has shed light on a possible 
structural involvement of this amino acid in the ω-ATAs homo-dimerization and stabilization. 
This finding has significant implications for omega transaminase structure-stability-solubility 
understanding and represents one of the first works about a rational approach aimed at improving 
recombinant ω-ATAs solubility. Further studies will be addressed to VPTA crystallization and 
tertiary structure investigation in order to understand the real effect of T16F mutation on the protein 
soluble folding. 
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